Means and methods for treating subjects with her2 and her3 positive cancer

JP2024071393A5Active Publication Date: 2024-11-12MELS BE FE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024030027
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-10-24
Filing Date
2024-02-29
Publication Date
2024-11-12
Estimated Expiration
2040-10-23

AI Technical Summary

Technical Problem

Current treatments for ErbB-2 and ErbB-3 positive cancers, particularly those with NRG1 fusion genes, often lead to recurrence and metastasis, and existing therapies like TKIs and monospecific antibodies show limited efficacy and resistance.

Method used

A bispecific antibody that binds to the extracellular portions of both ErbB-2 and ErbB-3, targeting NRG1 fusion genes, is used to treat cancers that have progressed after chemotherapy or TKI treatment, combining antigen binding sites to inhibit signaling and heterodimerization.

Benefits of technology

The bispecific antibody effectively stabilizes tumors and prevents further growth, offering a therapeutic benefit even in cases resistant to monospecific treatments, with a good safety profile and large therapeutic window.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000048_0000
    Figure 00000048_0000
  • Figure 00000048_0001
    Figure 00000048_0001
  • Figure 00000048_0002
    Figure 00000048_0002
Patent Text Reader

Abstract

To provide therapeutic (human) antibodies for the treatment of a subject with an ErbB-2 / ErbB-3 positive cancer.SOLUTION: The invention relates to a treatment using a bispecific antibody that comprises a first antigen-binding site that binds an extracellular part of ErbB-2 and a second antigen-binding site that binds an extracellular part of ErbB-3 for subjects that have cancer that has progressed after receiving a prior treatment. The prior treatment comprises a chemotherapy, a monospecific bivalent antibody comprising antigen-binding sites that bind an extracellular part of ErbB-2 or an extracellular part of ErbB-3, or a prior treatment with a tyrosine kinase inhibitor (TKI) of ErbB-2 or with a combination thereof.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of antibodies. In particular, the present invention relates to the field of therapeutic (human) antibodies for the treatment of subjects suffering from ErbB-2 / ErbB-3 positive cancers. More particularly, the present invention relates to treating cancers containing the Neuregulin-1 (NRG1) fusion gene, which contains at least a portion of the NRG1 gene fused to sequences from different chromosomal locations. [Background technology]

[0002] Proteolytic processing of the extracellular domain of the transmembrane NRG1 isoform releases soluble factors. HRG1-β1 is one of the proteins encoded by this gene. HRG1-β1 contains an Ig domain and an EGF-like domain required for direct binding to the receptor tyrosine kinases ErbB-3 and ErbB-4. The NRG1 gene and its isoforms are known under several different aliases: neuregulin 1; Pro-NRG1; HRGA; SMDF; HGL; GGF; NDF; NRG1 intronic transcript 2 (non-protein coding); heregulin, alpha (45 kD, ERBB2 P185 activator); acetylcholine receptor-inducing activity; neuregulin precursor 1, membrane-bound isoform; sensory neuron and motor neuron-derived factor; Neu differentiation factor; glial growth factor 2; NRG1-IT2; MSTP131; MST131; ARIA; GGF2; HRG1, and HRG. The external Ids for the NRG1 gene are HGNC:7997, Entrez Gene:3084, Ensembl:ENSG00000157168; OMIM:142445, and UniProtKB:Q02297.

[0003] Isoforms of NRG1 are generated by alternative splicing and include transmembrane, outer membrane-bound, decidual, secreted or intracellular forms (Falls, 2003; Hayes and Gullick, 2008). These isoforms are understood to bind ErbB-3 or ErbB-4, which signal heterodimerization with ErbB-2 (HER2). Although the protein encoded by NRG1 is usually considered a mitogen, the protein can also be strongly proapoptotic. Notably, intracellular expression of NRG1 can induce apoptosis of expressing cells Weinstein et al. (1998). Oncogene 17:2107-2113.

[0004] NRG1 gene fusions are understood to be oncogenic drivers. In PCT / NL2018 / 050206, the inventors reported the ability to target and treat cancers harboring NRG1 fusions, including NRG1 fusions, with bispecific antibodies targeting ErbB-2 and ErbB-3. In recent years, clinical responses to tyrosine kinase inhibitors (TKIs) and mAbs have been reported (Drilon A et al(2018),Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers.Cancer Discov Vol 8:686-95.Gay ND et al(2017),Durable response to afatinib in lung adenocarcinoma harboring NRG1 gene fusions.J Thorac Oncol 12:e107-10.Jones MR et al(2017),Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.Ann Oncol Vol.28:3092-7, and Cheema PK et al(2017),A case of invasive mucinous pulmonary adenocarcinoma with a CD74-NRG1 fusion protein targeted with afatinib.J Thorac Oncol 12:e200-2). Targeting of the signaling axis can be directed at different steps and parts of the signaling pathway. Among these are therapies directed at ErbB-2, ErbB-3, or both. Pharmaceuticals can be directed at the extracellular and / or intracellular parts of this molecule. Antibodies such as trastuzumab bind to ErbB-2 and inhibit its signaling. Therapeutic ErbB-3-directed antibodies have also been described.

[0005] Regarding the above-mentioned clinical reports, a certain level of efficacy has been reported, ranging from stable disease to limited and durable partial responses, but it has been observed that tumors may progress to destruction durability, recur, or metastasis of the original tumor may be detected. Such recurrences and metastases are often more resistant to pharmaceutical treatment. In the present invention, the inventors have identified that recurrence, progression, or metastasis after tumor treatment with TKI, chemotherapy, anti-ErbB-2 or anti-ErbB-3 targeting molecules can be successfully treated with a bispecific antibody comprising a first antigen-binding site that binds the extracellular portion of ErbB-2 and a second antigen-binding site that binds the extracellular portion of ErbB-3. Summary of the Invention

[0006] The present invention provides a bispecific antibody comprising a first antigen binding site that binds the extracellular portion of ErbB-2 and a second antigen binding site that binds the extracellular portion of ErbB-3 for use in treating a subject with an ErbB-2 and ErbB-3 positive cancer, wherein cells of the cancer comprise a neuregulin-1 (NRG1) fusion gene that comprises at least a portion of an NRG1 fusion gene fused to sequences from different chromosomal locations, and wherein the cancer in the subject has already progressed after receiving chemotherapy, prior treatment with a monospecific bivalent antibody comprising an antigen binding site that binds the extracellular portion of ErbB-2 or the extracellular portion of ErbB-3, or prior treatment with a tyrosine kinase inhibitor (TKI) of ErbB-2, or a combination thereof.

[0007] The subject is preferably a human subject.

[0008] Chemotherapy according to the present invention preferably comprises gemcitabine, capecitabine, carboplatin, a taxane such as docetaxel or paclitaxel, 5-fluorouracil (with or without radiotherapy), vinorelbine, mitoxantrone, vinblastine, cisplatin (or pemetrexed), oxaliplatin, carboplatin, ifosfamide, mitomycin C, vindesine, etoposide, Folfox (i.e. a combination of 5-fluorouracil, leucovorin, and oxaliplatin) or Folfiri (i.e. a combination of leucovorin, 5-fluorouracil and irinotecan), Folfirinox (a combination of leucovorin, 5-fluorouracil, irinotecan and oxaliplatin) or any combination thereof.

[0009] The monospecific bivalent antibody comprising an antigen-binding site that binds the extracellular portion of ErbB-2 is preferably trastuzumab, pertuzumab, or trastuzumab-emtansine. The ErbB-2 TKI is preferably one or more of lapatinib, canertinib, neratinib, tucatinib (irvitinib), CP-724714, taloxitinib, mubritinib, afatinib, valitinib, and dacomitinib, preferably afatinib.

[0010] In one embodiment, the ErbB-2 TKI is afatinib.

[0011] Monospecific bivalent antibodies comprising an antigen-binding site that binds the extracellular part of ErbB-3 preferably comprise patritumab, seribantumab, lumuletuzumab, elgemtumab, GSK2849330, KTN3379 or AV-203.

[0012] Previous treatments for cancer progression preferably include chemotherapy, TKI, ErbB-2 or ErB-3 targeted tumor treatments, as previously described herein. Treatments targeting ErbB-2 preferably use monospecific bivalent antibodies that contain an antigen binding site that binds the extracellular portion of ErbB-2. Such antibodies are preferably trastuzumab, pertuzumab, or trastuzumab-emtansine. Treatments targeting ErbB-2 preferably are ErbB-2 TKIs. The ErbB-2 TKI is preferably one or more of lapatinib, canertinib, neratinib, tucatinib (or irvitinib), CP-724714, taloxitinib, mubritinib, afatinib, valitinib, and dacomitinib, preferably afatinib. ErbB-2 TKIs can also affect ErbB-1 signaling, but differ from ErbB-1 TKIs in that they have significant activity against ErbB-2. Therapies targeting ErbB-3 preferably use monospecific bivalent antibodies that contain an antigen binding site that binds the extracellular portion of ErbB-3. Such antibodies are preferably patritumab, seribantumab, lumuletuzumab, elgemutumab, GSK2849330, KTN3379 or AV-203.

[0013] Target-specific therapies may be combined with other therapies directed against the same target, or a treatment that targets one target may also be effective against another of the targets mentioned.

[0014] The NRG1 fusion gene preferably comprises at least the 3' end of the NRG1 gene fused to a 5' sequence from a different chromosomal location. When present in a cancer cell, the cancer cell is preferably driven by the NRG1 fusion gene. The NRG1 fusion gene preferably expresses a protein comprising the NRG1 EGF-like domain. In some embodiments, the NRG1 fusion gene is a fusion of NRG1 with a gene on human chromosome 8. The gene on human chromosome 8 preferably encodes an excreted protein or a cell membrane-bound protein. In some embodiments, the NRG1 fusion gene is a fusion gene that ... , RAB3IL1, RBPMS, ROCK1, SDC4, SETD4, SLC3A2, SLC4A4, SMAD4, STAU3, THAP7, THBS1, TNC, TNFRSF10B, TNKS, TSHZ2, VAMP2, VTCN1, WHSC1L1, WRN and ZMYM2, preferably a fusion with the 5' sequence of SDC4; ATP1B1; or CD74 fusion, more preferably an SDC4-NRG1 fusion. In a preferred embodiment, the NRG1 fusion gene is a fusion of the 3' end of the NRG1 gene with the 5' sequence of the gene SDC4. In some cases, the NRG1 fusion gene is a fusion of the 5' end of the NRG1 gene with the 3' sequence of a fusion partner. In a preferred embodiment, the 5'NRG1 fusion encompasses a gene selected from the group consisting of FOXA1, PMEPA1, RAD51 and STMN2. In all of these cases, it is preferred that the gene fusion protein product be translated into a protein that contains the NRG1 EGF-like domain.

[0015] The cancer is preferably a recurrent or metastatic cancer. Recurrence typically refers to local recurrence, meaning that the cancer is in the same place as the original cancer or very close to that place. A tumor is typically said to be a metastatic tumor when it has migrated to lymph nodes or tissues near the original cancer or spread to more distant organs or tissues far from the original cancer. The difference between recurrence and metastasis is not always very clear when the tumor is more or less in the same place as the original tumor. In such cases, both indications can be used.

[0016] The cancer is preferably pancreatic cancer, pancreatic ductal adenocarcinoma, sarcoma, bladder cancer, colon cancer, gallbladder cancer, head and neck cancer, prostate cancer, uterine cancer, breast cancer, ovarian cancer, liver cancer, endometrial cancer, lung cancer such as non-small cell lung cancer, preferably non-small cell lung cancer, more preferably invasive mucinous adenocarcinoma.Preferably, the cancer is pancreatic ductal adenocarcinoma, and the tumor genome shows no mutation in one or more genes selected from the group consisting of EGFR, KRAS, cKIT-BRCA1-2, MET, ROS, RET, ALK, preferably KRAS.Thus, preferably, the cancer is pancreatic ductal adenocarcinoma, and the tumor genome is KRAS wild type.

[0017] A bispecific antibody comprising a first antigen-binding site that binds the extracellular portion of ErbB-2 and a second antigen-binding site that binds the extracellular portion of ErbB-3 preferably has a first antigen-binding site that binds domain I of ErbB-2 and a second antigen-binding site that binds domain III of ErbB-3. In some embodiments, the affinity of the first antigen-binding site for ErbB-2 is lower than the affinity of the second antigen-binding site for ErbB-3.

[0018] The bispecific antibody is preferably i) at least the CDR1, CDR2, and CDR3 sequences of an ErbB2-specific heavy chain variable region selected from the group consisting of MF2926, MF2930, MF1849; MF2973, MF3004, MF3958, MF2971, MF3025, MF2916, MF3991, MF3031, MF2889, MF2913, MF1847, MF3001, MF3003, and MF1898; or MF2973, MF3004, MF3958, MF2971, MF3025, MF2916, MF3991, MF3031, MF2889, MF2913, MF1847, MF3001, MF3003, or MF1898, and / or ii) at least the CDR1, CDR2, and CDR3 sequences of an ErbB3-specific heavy chain variable region selected from the group consisting of MF3178; MF3176; MF3163; MF3099; MF3307; MF6055; MF6056; MF6057; MF6058; MF6059; MF6060; MF6061; MF6062; MF6063; MF6064; MF6065; MF6066; MF6067; MF6068; MF6069; MF6070; MF6071; MF6072; MF6073 and MF6074, or the antibody is MF317 8;MF3176;MF3163;MF3099;MF3307;MF6055;MF6056;MF6057;MF6058;MF6059;MF6060;MF6061;MF6062;MF6063;MF6064;MF6065;MF6066;MF6067;MF6068;MF6069;MF6070;MF6071;MF6072;MF6073 or MF6074 include CDR sequences which differ by up to 3 amino acids, preferably up to 2 amino acids, preferably up to 1 amino acid.

[0019] In one embodiment, the bispecific antibody comprises: i) an ErbB2-specific heavy chain variable region sequence selected from the group consisting of the heavy chain variable region sequences of MF2926, MF2930, and MF1849; The antibody has a heavy chain variable region sequence that differs by up to 15 amino acids from the heavy chain variable region sequence of MF2926, MF2930, MF1849; MF2973, MF3004, MF3958, MF2971, MF3025, MF2916, MF3991, MF3031, MF2889, MF2913, MF1847, MF3001, MF3003, or MF1898, and / or ii) an ErbB3-specific heavy chain variable region sequence selected from the group consisting of the heavy chain variable region sequences of MF3178; MF3176; MF3163; MF3099; MF3307; MF6055; MF6056; MF6057; MF6058; MF6059; MF6060; MF6061; MF6062; MF6063; MF6064; MF6065; MF6066; MF6067; MF6068; MF6069; MF6070; MF6071; MF6072; MF6073 and MF6074; or the antibody is The CDR1, CDR2, and CDR3 sequences of F3178;MF3176;MF3163;MF3099;MF3307;MF6055;MF6056;MF6057;MF6058;MF6059;MF6060;MF6061;MF6062;MF6063;MF6064;MF6065;MF6066;MF6067;MF6068;MF6069;MF6070;MF6071;MF6072;MF6073 or MF6074 include heavy chain variable region sequences which differ by up to 15 amino acids.

[0020] In a preferred embodiment, the ErbB-2-binding variable domain of the bispecific antibody comprises at least the CDR1, CDR2, and CDR3 sequences of the ErbB2-specific heavy chain variable region MF3958, and the ErbB-3-binding variable domain of the bispecific antibody comprises at least the CDR1, CDR2, and CDR3 sequences of the ErbB3-specific heavy chain variable region MF3178.

[0021] The variable domain comprising the first antigen-binding site and the variable domain comprising the second antigen-binding site of the bispecific antibody are preferably light chain variable regions comprising an IgVKl-39 gene segment, most preferably a rearranged germline human kappa light chain IgVKl-39. * 01 / IGJKl * Including 01.

[0022] The variable domain comprising the first antigen-binding site and the variable domain comprising the second antigen-binding site of the bispecific antibody preferably comprise a light chain variable region comprising a CDR1 having the sequence (RASQSISSYLN), a CDR2 having the sequence (AASSLQS) and a CDR3 having the sequence (QQSYSTPPT), according to the KABAT numbering or according to the IMGT numbering system, wherein the CDRs are QSISSY, AAS and QQSYSTPPT, respectively.

[0023] The variable domain comprising the first antigen-binding site and the variable domain comprising the second antigen-binding site of the bispecific antibody preferably comprise the light chain variable region of Figure 1a or b.

[0024] The invention further provides a method of treating a subject having an ErbB-2 and ErbB-3 positive cancer, wherein cells of the cancer comprise an NRG1 fusion gene comprising at least a portion of the NRG1 gene fused to a sequence from a different chromosomal location, and the subject is a pre-treated cancer subject that has undergone prior chemotherapy or tumor therapy targeted to ErbB-2 or ErbB-3, the method comprising administering to a subject in need thereof a bispecific antibody comprising a first antigen binding site that binds an extracellular portion of ErbB-2 and a second antigen binding site that binds an extracellular portion of ErbB-3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] An NRG1 fusion gene comprises at least a portion of the NRG1 gene fused to a sequence from a different chromosomal location. "At least a portion" indicates that the entire NRG-1 gene may be present in the fusion or a portion thereof. The fusion preferably has coding sequences of at least exons 6, 7 and 8. Preferably, the NRG1 portion in the NRG1 fusion gene comprises the EGF-like domain of NRG1. At least a portion of the NRG1 gene may be fused to a sequence from a different chromosomal location such that the sequence is located 5' or 3' to at least a portion of the NRG1 gene.

[0026] Preferably, the 3' end of the NRG1 gene may be fused to a 5' sequence from a different chromosomal location. The NRG1 gene encodes various isoforms of NRG1. The various isoforms and their predicted functions are described in Adelaide et al (2003). The GGF and GGF2 isoforms contain a kringle-like sequence plus Ig and EGF-like domains, while the SMDF isoform shares only the EGF-like domain with the other isoforms. The EGF-like domain is encoded by the 3' end of this gene. The EGF-like domain is present in all NRG1 fusion genes of the invention. It has been found that the 5' from a different chromosomal location contains an excretion signal and / or a transmembrane domain of a cell membrane protein with at least one extracellular domain. An example is the CD74-NRG1 fusion. The 5' sequence from a different chromosomal location may also insert a sequence that activates the transcription of NRG1, an example being a promoter or enhancer. This 5' sequence is typically a sequence from a different gene than NRG1. This sequence can include coding regions, expression control sequences such as promoters or enhancers, or combinations thereof. The NRG fusion includes 5' sequences from different locations, and can be from different chromosomes or from another part of chromosome 8. In a preferred embodiment, the 5' sequence is from a gene on human chromosome 8.

[0027] The 3' end of the NRG1 gene, e.g., NRG-1 gene, in the fusion preferably has at least the coding sequence of exons 6, 7 and 8. Another way to define the NRG1 portion in the NRG1 fusion gene is to include the EGF-like domain of NRG1. This domain is encoded by the 3' end of the NRG1 gene (exons 6-8) and is necessary for binding to ErbB-3. The NRG1 fusion retains an in-frame coding region for this EGF-like domain at the 3' end of the fusion. The EGF-like domain is typically about 30-40 amino acid residues in length, the prototype of which is found in the sequence of epidermal growth factor (EGF) (PMID:2288911, PMID:6334307, PMID:1522591, PMID:6607417, PMID:3282918, PMID:11498013). EGF-like domains are known to exist in more or less conserved form in many other, mainly animal, proteins. A common feature of EGF-like domains is that they are found in the extracellular domains of membrane-bound proteins or in proteins known to be secreted (exception: prostaglandin G / H synthase).

[0028] The NRG1 fusion gene is preferably a fusion gene comprising the 3' end of the NRG1 gene and one of the following: ADAM9, AKAP13, APP, ATP1B1, BMPR1B, CCND1, CD44, CD74, CDH1, CDH6, CDK1, CLU, COX10-AS1, DIP2B, DOC4, DPYSL2, FOXA1, GDF15, HMBOX1, KIF13B, MCPH1, MDK, MRPL13, NOTCH2, PARP8, PDE7A, POMK, RAB2IL1, R The fusion gene is a fusion with the 5' sequence of one of the genes selected from the group consisting of AB3IL1, RBPMS, ROCK1, SDC4, SETD4, SLC3A2, SLC4A4, SMAD4, STAU3, THAP7, THBS1, TNC, TNFRSF10B, TNKS, TSHZ2, VAMP2, VTCN1, WHSC1L1, WRN and ZMYM2, preferably an SDC4, ATP1B1 or CD74 fusion, more preferably an SDC4-NRG1 fusion. In a preferred embodiment, the NRG1 fusion gene is a fusion of the 3' end of the NRG1 gene with the 5' sequence of the gene SDC4. In some cases, the NRG1 fusion gene is a fusion of the 5' end of the NRG1 gene with the 3' sequence of a fusion partner. In a preferred embodiment, the 5'NRG1 fusion encompasses a gene selected from the group consisting of FOXA1, PMEPA1, RAD51 and STMN2. In all of these cases, it is preferred that the gene fusion protein product be translated into a protein that contains the NRG1 EGF-like domain.

[0029] The NRG1 fusion gene is preferably a fusion of the 3' end of the NRG1 gene with the 5' sequences of the SDC4 gene.

[0030] An NRG1 fusion gene may be a fusion of at least a portion of the NRG1 gene with a sequence from a different chromosomal location located 3' to the NRG1 gene. Such an NRG1 fusion gene may be a fusion of at least a portion of the NRG1 gene with a sequence from a different chromosomal location located 3' to the NRG1 gene, CD74, STMN2, PMEPA1, PROSC, or PSAP.

[0031] The receptors for all NRG1 isoforms are the ErbB family of tyrosine kinase transmembrane receptors. This family is also referred to as the human epidermal growth factor (EGF) receptor family (HER). This family has four members, ErbB (erythroblastoma)-1, ErbB-2, ErbB-3, and ErbB-4. These receptors (reviewed in Yarden and Pines 2012) are widely expressed on epithelial cells. Upregulation of HER receptors or HER receptor ligands, such as heregulin (HRG) or epidermal growth factor (EGF), is a frequent event in human cancers (Wilson, Fridlyand et al. 2012). Overexpression of ErbB-1 and ErbB-2 occurs especially in epithelial tumors and is associated with tumor invasion, metastasis, resistance to chemotherapy, and poor prognosis (Zhang, Berezov et al. 2007). In normal breast, ErbB-3 has been shown to be important in the growth and differentiation of luminal epithelium. For example, loss / inhibition of ErbB-3 results in selective proliferation of basal over luminal epithelium (Balko, Miller et al. 2012). Ligand binding to the extracellular domain of RTK induces receptor dimerization, both between the same receptor subtype (homodimerization) and different receptor subtypes (heterodimerization). Dimerization can activate the intracellular tyrosine kinase domain, which undergoes autophosphorylation and can then activate several downstream pro-growth signaling pathways, including those mediated by mitogen-activated protein kinases (MAPKs) and the pro-survival pathway Akt (reviewed in Yarden and Pines, 2012). No specific endogenous ligand has been identified for ErbB-2, and it is therefore assumed that it normally signals via heterodimerization (Sergina, Rausch et al. 2007). ErbB-3 can be activated by the binding of its ligands, including, but not limited to, neuregulin (NRG) and heregulin (HRG).

[0032] ErbB-1 is known by various synonyms, the most common of which is EGFR. EGFR has an extracellular domain (ECD) composed of four subdomains, two of which are involved in ligand binding and two of which are involved in homodimerization and heterodimerization. EGFR integrates extracellular signals from various ligands to obtain diverse intracellular responses. EGFR is involved in several human epithelial malignancies, especially cancers of the breast, bladder, non-small cell lung, colon, ovary, head and neck, and brain. Activating mutations in the gene and overexpression of the receptor and its ligands have been found, resulting in an autocrine activation loop. This receptor tyrosine kinase (RTK) is widely used as a target for cancer therapy. Both small molecule inhibitors targeting the RTK and monoclonal antibodies (mAbs) (monospecific bivalent) directed against the extracellular ligand binding domain have been developed, which have shown some clinical success so far. The database accession number for the human EGFR protein and the gene encoding it is (GenBank NM_005228.3). This accession number is provided primarily to provide an additional method of identifying the EGFR protein as a target, and the actual sequence of the EGFR protein bound by an antibody may vary due to mutations in the encoding gene, such as those that occur in some cancers.

[0033] The term "ErbB-2" as used herein refers to the protein encoded by the ERBB-2 gene in humans. Alternative names for this gene or protein include CD340, HER-2; HER-2 / neu, MLN19; NEU; NGL; TKR1; the ERBB-2 gene is often referred to as HER2 (human epidermal growth factor receptor 2). When ErbB-2 is mentioned herein, the reference refers to human ErbB-2. An antibody that contains an antigen binding site that binds to ErbB-2 binds to human ErbB-2. The ErbB-2 antigen binding site also binds to other mammalian orthologs due to sequence and tertiary structure similarities between such orthologs, but this is not necessarily the case. The database accession numbers for human ErbB-2 protein and the gene encoding it are (NP_001005862.1, NP_004439.2, NC_000017.10, NT_010783.15, NC_018928.2). This accession number is provided primarily to provide an additional method of identifying ErbB-2 as a target, and the actual sequence of the ErbB-2 protein bound by the antibody may vary due to mutations in the encoding gene, such as those that occur in some cancers. The ErbB-2 antigen binding site binds ErbB-2 and various variants thereof, such as those expressed by some ErbB-2 positive tumor cells. The antigen binding site that binds ErbB-2 preferably binds domain I of ErbB-2.

[0034] The term "ErbB-3" as used herein refers to the protein encoded by the ERBB3 gene in humans. Alternative names for the gene or protein are HER3; LCCS2; MDA-BF-1; c-ErbB-3, c-ErbB3; ErbB3-S; p180-ErbB3; p45-sErbB3; and p85-sErbB3. When ErbB-3 is mentioned herein, the reference refers to human ErbB-3. An antibody that contains an antigen binding site that binds ErbB-3 binds human ErbB-3. Due to sequence and tertiary structure similarities between human and other mammalian orthologs, the ErbB-3 antigen binding site may, but does not necessarily, also bind such orthologs. The database accession numbers for human ErbB-3 protein and the gene encoding it are (NP_001005915.1, NP_001973.2, NC_000012.11, NC_018923.2, NT_029419.12). This accession number is provided primarily to provide an additional method of identifying ErbB-3 as a target, and the actual sequence of the ErbB-3 protein bound by the antibody may vary due to mutations in the encoding gene, such as those that occur in some cancers. The ErbB-3 antigen binding site binds ErbB-3 and its various variants, such as those expressed by some ErbB-3 positive tumor cells. The antigen binding site that binds ErbB-3 preferably binds domain III of ErbB-3.

[0035] When reference is made to ErbB-1, ErbB-2 or ErbB-3, or alternative names thereof, the reference is to human ErbB-1, ErbB-2 or ErbB-3. The antibodies referred to herein bind to ErbB-1, ErbB-2 or ErbB-3, and to many mutant ErbB-1, ErbB-2 or ErbB-3 proteins that can be found in cancer.

[0036] CD74 is known under a number of aliases. Some of these are CD74 molecule; CD74 antigen (major histocompatibility complex, class II antigen-associated invariant polypeptide); CD74 molecule, major histocompatibility complex, class II invariant chain; HLA-DR antigen-associated invariant chain; class II antigen gamma chain; Ia-associated invariant chain; MHC HLA-DR gamma chain; HLA-DR-gamma; DHLAG; P33; HLA class II histocompatibility antigen gamma chain; Ia antigen-associated invariant chain; Ia-gamma and HLADG. External Ids for CD74 are HGNC: 1697; Entrez Gene: 972; Ensembl: ENSG00000019582; OMIM: 142790, and UniProtKB: P04233.

[0037] DOC4 or teneurin transmembrane protein 4 (TENM4) is known by several different names, including, but not limited to, Protein Odd Oz / Ten-M homolog 4; tenascin-M4; Ten-M4; Ten-4; ODZ4; TNM4; Odz, Odd Oz / Ten-M homolog 4 (Drosophila); Odz, Odd Oz / Ten-M homolog 4; teneurin-4; KIAA1302; Doc4; and ETM5. External Ids for DOC4 are HGNC:29945; Entrez Gene:26011; Ensembl:ENSG00000149256; OMIM:610084, and UniProtKB:Q6N022.

[0038] TNFRSF10B or TNF receptor superfamily member 10b is known by several different names, including, for example, tumor necrosis factor receptor superfamily, member 10b; TNF-related apoptosis-inducing ligand receptor 2; death receptor 5; TRAIL-R2; TRAILR2; KILLER, TRICK2; ZTNFR9; DR5; p53-regulated DNA damage-inducible death receptor (killer), tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor-like protein ZTNFR9, death domain containing receptor for TRAIL / Apo-2L, poptosis-inducing protein TRICK2A / 2B; apoptosis-inducing receptor TRAIL-R2, cytotoxic TRAIL receptor-2, Fas-like protein, TRAIL receptor 2; CD262 antigen; KILLER / DR5, TRICK2A; TRICK2B; TRICKB, and CD262. The external Ids for TNFRSF10B are HGNC:11905; Entrez Gene:8795; Ensembl:ENSG00000120889; OMIM:603612, and UniProtKB:O14763.

[0039] The CLU gene or clusterin is known by several different names, such as Testosterone-Repressed Prostate Message 2; Apolipoprotein J; Complement-Related Protein SP-40,40; Complement Cytolysis Inhibitor; Complement Lysis Inhibitor; Sulfated Glycoprotein 2; Ku70-Binding Protein 1; NA1 / NA2TRPM-2; APO-J; APOJ; KUB1; CLI; Clusterin (Complement Lysis Inhibitor, SP-40,40, Sulfated Glycoprotein 2, Testosterone-Repressed Prostate Message 2, Apolipoprotein J); Age-Related Gene 4 Protein; Age-Related Protein 4; SGP-2; SP-40; TRPM2; AAG4; CLU1; CLU2; and the SGP2 external Id for CLU is HGNC:2095; Entrez Gene:1191; Ensembl:ENSG00000120885; OMIM:185430, and UniProtKB:P10909.

[0040] VAMP2 or vesicle-associated membrane protein 2 is known by several different names, such as synaptobrevin 2; SYB2; vesicle-associated membrane protein 2; and synaptobrevin-2. The external Ids for VAMP2 are HGNC: 12643; Entrez Gene: 6844; Ensembl: ENSG00000220205; OMIM: 185881, and UniProtKB: P63027.

[0041] SLCA3A2 or solute carrier family 3 member 2 is known by several different names, such as lymphocyte activation antigen 4F2 large subunit; solute carrier family 3 (activator of dibasic and neutral amino acid transport), member 2; antigen identified by monoclonal antibodies 4F2, TRA1.10, TROP4, and T43; solute carrier family 3 (amino acid transporter heavy chain), member 2; 4F2 cell surface antigen heavy chain; CD98 heavy chain; 4F2HC; MDU1; antigen defined by monoclonal antibody 4F2, heavy chain; antigen defined by monoclonal antibody 4F2; 4F2 heavy chain antigen; 4F2 heavy chain; CD98 antigen; CD98HC; 4T2HC; NACAE; CD98 and 4F2. The external IDs for SLC3A2 are HGNC:11026; Entrez Gene:6520; Ensembl:ENSG00000168003; OMIM:158070, and UniProtKB:P08195.

[0042] RBPMS or RNA binding proteins with multiple splicing are known by several different names, such as RNA binding proteins with multiple splicing; heart and RRM expressed sequence; HERMES; RNA binding proteins with multiple splicing; and RBP-MS. The external Ids for RBPMS are HGNC:19097; Entrez Gene:11030; Ensembl:ENSG00000157110; OMIM:601558, and UniProtKB:Q93062.

[0043] WRN or Werner syndrome RecQ-like helicase is known by several different names, such as Werner syndrome RecQ-like helicase; DNA helicase, RecQ-like type 3; RecQ protein-like 2; Exonuclease WRN; RECQL2; RECQ3; Werner syndrome ATP-dependent helicase; Werner syndrome, RecQ helicase-like; Werner syndrome; EC3.6.4.12; EC3.1.-.-; EC3.6.1; and RECQL3. The external Ids for WRN are HGNC:12791; Entrez Gene:7486; Ensembl:ENSG00000165392; OMIM:604611, and UniProtKB:Q14191.

[0044] SDC4 or syndecan 4 is known by several different names, such as syndecan 4 (amphiglycan, ryudocan); syndecan proteoglycan 4; ryudocan core protein; amphiglycan; SYND4; ryudocan amphiglycan; and syndecan-4. The external Ids for SDC4 are HGNC:10661; Entrez Gene:6385; Ensembl:ENSG00000124145; OMIM:600017, and UniProtKB:P31431.

[0045] ADAM9 or a disintegrin and metalloproteinase domain 9 (meltrin gamma) is known by several different names, such as ADAM metallopeptidase domain; a disintegrin and metalloproteinase domain-containing protein 9; metalloprotease / disintegrin / cysteine-rich protein 9; cellular disintegrin-related protein; myeloma cell metalloproteinase; cone-rod dystrophy 9; MCMP; MDC9; ADAM metallopeptidase domain 9 (meltrin gamma); meltrin-gamma; meltrin gamma; EC3.4.24.; EC3.4.24; KIAA0021; CORD9; MLTNG. External Ids for the ADAM9 gene are HGNC:216; Entrez Gene:8754; Ensembl:ENSG00000168615; OMIM:602713, and UniProtKB:Q13443.

[0046] AKAP13 or A-kinase anchoring protein 13 is known by several different names, including lymphoid blastoid oncogene; breast cancer nuclear receptor-binding accessory protein; non-oncogene Rho GTPase-specific GTP exchange factor; guanine nucleotide exchange factor Lbc; protein kinase A-anchoring protein 13; human thyroid anchoring protein 31; A-kinase (PRKA) anchoring protein 13; A-kinase anchoring protein 13; LBC oncogene; AKAP-Lbc; AKAP-13; PRKA13; LBC; BRX; P47; proto-LBC; ARHGEF13; proto-LB; C-Lbc; HA-3; Ht31; and HT31. The external Ids for the AKAP13 gene are HGNC:371; Entrez Gene:11214; Ensembl:ENSG00000170776; OMIM:604686, and UniProtKB:Q12802.

[0047] APP, or amyloid beta precursor protein, is known by several different names and is believed to be, for example, amyloid beta (A4) precursor protein; Alzheimer's disease amyloid protein; cerebrovascular amyloid peptide; amyloid beta precursor protein; amyloid precursor protein; amyloid beta A4 protein; peptidase nexin-II; protease nexin-II; PreA4; PN-II; ABPP; APPI; CVAP; AD1; beta amyloid precursor protein; testicular tissue protein Li; beta amyloid peptide (1-40); beta amyloid peptide (1-42); amyloid beta A4 protein; beta amyloid peptide; Alzheimer's disease; CTF gamma; ABETA; AAA; PN2; and A4. The external Ids for the APP gene are HGNC:620; Entrez Gene:351; Ensembl:ENSG00000142192; OMIM:104760, and UniProtKB:P05067.

[0048] ATP1B1 is known by several different names, such as ATPase Na+ / K+ transport subunit beta 1; sodium / potassium transport ATPase subunit beta 1; sodium-potassium ATPase subunit beta 1 (non-catalytic); ATPase, Na+ / K+ transport, beta 1 polypeptide; sodium pump subunit beta 1; ATP1B; sodium / potassium transport ATPase beta 1 chain; sodium / potassium-dependent ATPase beta 1 subunit; sodium / potassium-dependent ATPase subunit beta 1; beta 1 subunit of Na(+),K(+)-ATPase; Na,K-ATPase beta 1 polypeptide; and adenosine triphosphatase. External Ids for the ATP1B1 gene are HGNC:804; Entrez Gene:481; Ensembl:ENSG00000143153; OMIM:182330, and UniProtKB:P05026.

[0049] BMPR1B is known by several different names, including bone morphoprotein receptor type 1B; bone morphoprotein receptor, type IB; bone morphoprotein receptor type 1B; BMP type 1B receptor; EC 2.7.11.30; BMPR-1B; serine / threonine receptor kinase; activin receptor-like kinase 6; CDw293 antigen; EC 2.7.11; CDw293; ALK-6; BDA1D; ALK6; AMDD, and BDA2. The external Ids for the BMPR1B gene are HGNC:1077; Entrez Gene:658; Ensembl:ENSG00000138696; OMIM:603248, and UniProtKB:O00238.

[0050] CCND1 or cyclin D1 is known by several different names and is believed to be, for example, B-cell lymphoma 1 protein; G1 / S-specific cyclin-D1; B-cell CLL / lymphoma 1; BCL-1 oncogene; PRAD1 oncogene; PRAD1; BCL1; cyclin D1 (PRAD1: parathyromatosis type 1), parathyromatosis type 1; G1 / S-specific cyclin D1; D11S287E; U21B31; and BCL-1. The external Ids for the CCND1 gene are HGNC: 1582; ​​Entrez Gene: 595; Ensembl: ENSG00000110092; OMIM: 168461, and UniProtKB: P24385.

[0051] CD44 is also known by several different names, such as CD44 molecule (Indian Blood Group); hematopoietic cell E and L-selective ligand; GP90 lymphocyte homing / adhesion receptor; chondroitin sulfate proteoglycan 8; extracellular matrix receptor III; heparan sulfate proteoglycan; phagocyte glycoprotein 1; hyaluronan receptor; Hermes antigen; CD44 antigen; ECMR-III; HUTCH-I; epican; MDU2; MDU3; MIC4; LHR; CD44 antigen (homing function and Indian blood group system); homing function and Indian blood group system; cell surface glycoprotein CD44; Indian Blood Group antigen; phagocyte glycoprotein I; soluble CD44; CDW44; CSPG8; HCELL; CDw44; PGP-1; MC56; Pgp1, and IN. The external Ids for the CD44 gene are HGNC:1681; Entrez Gene:960; Ensembl:ENSG00000026508; OMIM:107269, and UniProtKB:P16070.

[0052] CDH1 or cadherin 1 is known by several different names, such as cadherin 1, type 1, E-cadherin (epithelial); epithelial cadherin; cadherin-1; uvomorulin; E-cadherin; CAM120 / 80; CDHE; UVO; calcium-dependent adhesion protein, epithelial; epididymal secretory sperm-binding protein; cadherin 1, E-cadherin (epithelial); Cell-CAM120 / 80; CD324 antigen; E-cadherin 1; Arc-1; BCDS1; CD324; ECAD; and LCAM. The external Ids for the CDH1 gene are HGNC: 1748; Entrez Gene: 999; Ensembl: ENSG00000039068; OMIM: 192090, and UniProtKB: P12830.

[0053] CDH6 or cadherin 6 is known by several different names, such as cadherin 6, type 2, K-cadherin (fetal kidney); cadherin-6; K-cadherin; renal cadherin; CAD6, and KCAD. The external Ids for the CDH6 gene are HGNC:1765; Entrez Gene:1004; Ensembl:ENSG00000113361; OMIM:603007, and UniProtKB:P55285.

[0054] CDK1 or cyclin-dependent kinase 1 is known by several different names, such as cell division cycle 2, G1-S and G2-M; cell division control protein 2 homolog; cell division protein kinase 1; cyclin-dependent kinase 1; P34 protein kinase; P34CDC2; CDC28A; CDC2; cell cycle regulator CDC2; EC 2.7.11.22; EC 2.7.11.23; and CDKN1. The external Ids for the CDK1 gene are HGNC: 1722; Entrez Gene: 983; Ensembl: ENSG00000170312; OMIM: 116940, and UniProtKB: P06493.

[0055] COX10-AS1 or COX10 antisense RNA1 is known by several different names, and is believed to be, for example, COX10 antisense RNA1 (non-protein coding); COX10 antisense RNA (non-protein coding); COX10-AS; and COX10AS. The external Ids for the COX10-AS1 gene are HGNC:38873; Entrez Gene:100874058; and Ensembl:ENSG00000236088.

[0056] DIP2B or Disco interacting protein 2 homolog B is known by several different names, such as Disco interacting protein 2 homolog B; DIP2 Disco interacting protein 2 homolog B (Drosophila); DIP2 Disco interacting protein 2 homolog B; DIP2 homolog B; and KIAA1463. The external Ids for the DIP2B gene are HGNC:29284; Entrez Gene:57609; Ensembl:ENSG00000066084; OMIM:611379, and UniProtKB:Q9P265.

[0057] DPYSL2 or dihydropyrimidinase-like 2 is known by several different names and is believed to be, for example, dihydropyrimidinase-related protein 2; Unc-33-like phosphoprotein 2; CRMP-2; ULIP-2; CRMP2; DRP-2; ULIP2; N2A3; collapsin response mediator protein HCRMP-2; collapsin response mediator protein 2; dihydropyrimidinase-like 2; DHPRP2; and DRP2. The external Ids for the DPYSL2 gene are HGNC:3014; Entrez Gene:1808; Ensembl:ENSG00000092964; OMIM:602463, and UniProtKB:Q16555.

[0058] FGFR1 or fibroblast growth factor receptor 1 is known by several different names, such as basic fibroblast growth factor receptor 1; Fms-related tyrosine kinase 2; proto-oncogene C-Fgr; EC 2.7.10.1; BFGF-R-1; FGFR-1; BFGFR; FGFBR; FLT-2HBGFR; FLT2CEK; FLG; heparin-binding growth factor receptor; FMS-like tyrosine kinase 2; hydroxyaryl protein kinase; Fms-like tyrosine kinase 2; FGFR1 / PLAG1 fusion; Pfeiffer syndrome; CD331 antigen; EC 2.7.10; HRTFDS; CD331; N-SAM; N-Sam; ECCL; KAL2; HH2, and OGD. The external Ids for the FGFR1 gene are HGNC:3688; Entrez Gene:2260; Ensembl:ENSG00000077782; OMIM:136350, and UniProtKB:P11362.

[0059] FOXA1 or forkhead box A1 is known by several different names, including hepatocyte nuclear factor 3-alpha; forkhead box protein A1; transcription factor 3A; HNF-3-alpha; HNF-3A; TCF-3A; HNF3A; TCF3A; and hepatocyte nuclear factor 3, alpha. The external Ids for the FOXA1 gene are HGNC:5021; Entrez Gene:3169; Ensembl:ENSG00000129514; OMIM:602294, and UniProtKB:P55317.

[0060] GDF15 or growth differentiation factor 15 is known by several different names, such as prostate differentiation factor; nonsteroidal anti-inflammatory drug-activated gene 1; placental bone morphogenetic protein; growth / differentiation factor 15; macrophage inhibitory cytokine 1; NSAID-activated gene 1 protein; NSAID-regulated gene 1 protein; placental TGF-beta; GDF-15; MIC-1; NAG-1; NRG-1; PTGFB; MIC1; PLAB; PDF; NSAID (nonsteroidal anti-inflammatory drug)-activated protein 1; macrophage inhibitory cytokine-1; PTGF-beta. External Ids for the GDF15 gene are HGNC:30142; Entrez Gene:9518; Ensembl:ENSG00000130513; OMIM:605312, and UniProtKB:Q99988.

[0061] HMBOX1 or homeobox-containing 1; homeobox telomere binding protein 1; telomere associated homeobox-containing protein 1; homeobox-containing protein 1; HOT1; homeobox-containing protein PBHNF; HNF1LA; PBHNF; and TAH1. The external Ids for the HMBOX1 gene are HGNC:26137; Entrez Gene:79618; Ensembl:ENSG00000147421; and UniProtKB:Q6NT76.

[0062] KIF13B or kinesin family member 13B is known by several different names, such as kinesin-like protein KIF13B; kinesin-like protein GAKIN; GAKIN; guanylate kinase-related kinesin; kinesin 13B; and KIAA0639. The external Ids for the KIF13B gene are HGNC:14405; Entrez Gene:23303; Ensembl:ENSG00000197892; OMIM:607350, and UniProtKB:Q9NQT8.

[0063] MCPH1 is known by several different names, such as microcephalin 1; BRCT repeat inhibitor of TERT expression 1; microcephalin; microcephaly, primary autosomal recessive 1; truncated microcephalin; BRIT1, and MCT. The external Ids for the MCPH1 gene are HGNC:6954; Entrez Gene:79648; Ensembl:ENSG00000147316; OMIM:607117, and UniProtKB:Q8NEM0.

[0064] MDK or midkine is known by several different names, such as neurite outgrowth promoting factor 2; neurite outgrowth promoting factor 2; amphiregulin-associated protein; midgestational and renal protein; NEGF2; ARAP; MK; neurite outgrowth promoting protein; retinoic acid-inducible factor; and MK1. External Ids for the MDK gene are HGNC:6972; Entrez Gene:4192; Ensembl:ENSG00000110492; OMIM:162096, and UniProtKB:P21741.

[0065] MRPL13, or mitochondrial ribosomal protein L13, is known by several different names and is believed to be, for example, mitochondrial large ribosomal subunit protein UL13m; 39S ribosomal protein L13, mitochondrial; MRP-L13; L13mt; RPML13; RPL13; L13A; and L13. The external Ids for the MRPL13 gene are HGNC:14278; Entrez Gene:28998; Ensembl:ENSG00000172172; OMIM:610200, and UniProtKB:Q9BYD1.

[0066] NOTCH2 or Notch receptor 2 is known by several different names, including, for example, Notch2; neurogenic locus Notch homolog protein 2; HN2; Notch (Drosophila) homolog 2; Notch homolog 2 (Drosophila); Notch homolog 2; HJCYS, and AGS2. The external Ids for the NOTCH2 gene are HGNC:7882; Entrez Gene:4853; Ensembl:ENSG00000134250; OMIM:600275, and UniProtKB:Q04721.

[0067] PARP8 or poly(ADP-ribose) polymerase family member 8 is known by several different names, including ADP-ribosyltransferase diphtheria toxin-like 16; protein mono-ADP-ribosyltransferase PARP8; poly[ADP-ribose]polymerase 8; ARTD16; EC2.4.2.30; EC2.4.2.-; PART16; and it is believed that it may be PARP-8. The external Ids for the PARP8 gene are HGNC:26124; Entrez Gene:79668; Ensembl:ENSG00000151883; and UniProtKB:Q8N3A8.

[0068] PDE7A or phosphodiesterase 7A is known by several different names, such as high affinity CAMP-specific 3',5'-cyclic phosphodiesterase 7A; HCP1; TM22; phosphodiesterase isozyme 7; EC 3.1.4.17; EC 3.1.4.53; EC 3.1.4; PDE7; external Ids for the PDE7A gene are HGNC:8791; Entrez Gene:5150; Ensembl:ENSG00000205268; OMIM:171885, and UniProtKB:Q13946.

[0069] POMK or protein O-mannose kinase is known by several different names and is believed to be, for example, protein kinase-like protein SgK196; Sugen kinase 196; SGK196; putative inactive protein kinase-like protein SgK196; protein-O-mannose kinase; EC 2.7.1.183; MDDGA12; and MDDGC12. The external Ids for the POMK gene are HGNC:26267; Entrez Gene:84197; Ensembl:ENSG00000185900; OMIM:615247, and UniProtKB:Q9H5K3.

[0070] RAB3IL1 is known by several different names, such as RAB3A-interacting protein-like 1; guanine nucleotide exchange factor for Rab-3A; RAB3A-interacting protein (rabin3)-like 1; Rab3A-interacting-like protein 1; rabin3-like 1; guanine nucleotide exchange factor for Rab3A; Rab-3A-interacting-like protein 1; and GRAB. The external Ids for the RAB3IL1 gene are HGNC:9780; Entrez Gene:5866; Ensembl:ENSG00000167994; and UniProtKB:Q8TBN0.

[0071] ROCK1 or Rho-associated coiled-coil-containing protein kinase 1 is known by several different names, such as renal cancer antigen NY-REN-35; Rho-associated protein kinase 1; P160 ROCK-1; EC 2.7.11.1; P160ROCKROCK-I; Rho-associated coiled-coil-containing protein kinase 1; Rho-associated coiled-coil-containing protein kinase I; EC 2.7.11.1; and EC 2.7.11. The external Ids for the ROCK1 gene are HGNC: 10251; Entrez Gene: 6093; Ensembl: ENSG00000067900; OMIM: 601702, and UniProtKB: Q13464.

[0072] SETD4 or SET domain containing 4 is known by several different names, such as SET domain containing protein 4; C21orf18; C21orf27; chromosome 21 open reading frame 27; chromosome 21 open reading frame 18; and EC2.1.1.-. The external Ids for the SETD4 gene are HGNC:1258; Entrez Gene:54093; Ensembl:ENSG00000185917; and UniProtKB:Q9NVD3.

[0073] SLC4A4 is known by a number of different names, including solute transporter family 4 member 4; solute transporter family 4 (sodium bicarbonate symporter), member 4; electrogenic sodium bicarbonate symporter 1; Na(+) / HCO3(-) symporter; KNBC1; NBC1; sodium bicarbonate symporter 1 (sodium bicarbonate symporter, kidney; sodium bicarbonate symporter, pancreas); solute transporter family 4, sodium bicarbonate symporter, member 4, brain-type; solute transporter family 4, sodium bicarbonate symporter, member 5; solute transporter family 4, sodium bicarbonate symporter, member 4; sodium bicarbonate symporter; NBCe1-A; SLC4A5; HNBC1; HhNMC; NBCE1; KNBC; NBC2; PNBC; NBC. The external Ids for the SLC4A4 gene are HGNC:11030; Entrez Gene:8671; Ensembl:ENSG00000080493; OMIM:603345, and UniProtKB:Q9Y6R1.

[0074] SMAD4 is known by several different names, such as SMAD family member 4; deletion target in pancreatic cancer 4; maternal for decapentaplegic homolog 4; MAD homolog 4; MADH4; DPC4; MAD, maternal for decapentaplegic homolog 4 (Drosophila); maternal for decapentaplegic, Drosophila, its homolog, 4; SMAD, maternal for DPP homolog 4 (Drosophila); deletion in pancreatic cancer locus 4; SMAD, maternal for DPP homolog; maternal for DPP homolog; SMAD4; HSMAD4; MYHRS; Smad4, and JIP. The external Ids for the SMAD4 gene are HGNC:6770; Entrez Gene:4089; Ensembl:ENSG00000141646; OMIM:600993, and UniProtKB:Q13485.

[0075] THAP7 is also known as THAP domain containing 7 or THAP domain containing protein 7. The external Ids for the THAP7 gene are HGNC:23190; Entrez Gene:80764; Ensembl:ENSG00000184436; OMIM:609518; and UniProtKB:Q9BT49.

[0076] THBS1 or thrombospondin 1 is known by a number of different names, such as thrombospondin-1p180; thrombospondin-1; glycoprotein G; TSP1; TSP; thrombospondin-P50; THBS-1; TSP-1; THBS. The external Ids for the THBS1 gene are HGNC:11785; Entrez Gene:7057; Ensembl:ENSG00000137801; OMIM:188060, and UniProtKB:P07996.

[0077] TNC or tenascin-C is known by several different names, such as glioma-associated extracellular matrix antigen; deaf, autosomal dominant 56; hexabrachion (tenascin); intertendinous antigen; neuronectin; cytotactin; GP150-225; tenascin; GMEM; TN-C; HXB; JI; TN; hexabrachion (tenascin-C, cytotactin); tenascin-C additional domain 1; tenascin-C isoform 14 / AD1 / 16; hexabrachion; tenascin-C; 150-225; DFNA56, and GP. The external Ids for the TNC gene are HGNC:5318; Entrez Gene:3371; Ensembl:ENSG00000041982; OMIM:187380, and UniProtKB:P24821.

[0078] TNKS or tankyrase is known by several different names, such as tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase; TRF1-interacting ankyrin-related ADP-ribose polymerase 1; protein poly-ADP-ribosyltransferase tankyrase-1; ADP-ribosyltransferase diphtheria toxin-like 5; poly[ADP-ribose]polymerase tankyrase-1; poly[ADP-ribose]polymerase 5A; tankyrase I; tankyrase-1; PARP5A; TNKS-1; ARTD5; PARPL; TANK1; TINF1; TNKS1; TIN1; TRF1-interacting ankyrin-related ADP-ribose polymerase; EC 2.4.2.30; EC 2.4.2.-; PARP-5a; and PART5. The external Ids for the TNKS gene are HGNC:11941; Entrez Gene:8658; Ensembl:ENSG00000173273; OMIM:603303, and UniProtKB:O95271.

[0079] TSHZ2 or Teashirt zinc finger homeobox 2 is known by several different names, such as zinc finger protein 218; ovarian cancer associated protein 10-2; Teashirt family zinc finger 2; Teashirt homolog 2; C20orf17; OVC10-2; ZNF218; TSH2; serologically defined colon cancer antigen 33-like; chromosome 20 open reading frame 17; cell growth inhibitory protein 7; and ZABC2. The external Ids for the TSHZ2 gene are HGNC:13010; Entrez Gene:128553; Ensembl:ENSG00000182463; OMIM:614118, and UniProtKB:Q9NRE2.

[0080] VTCN1 or V-set domain containing inhibitor of T cell activation 1 is known under several different names and is believed to be, for example, V-set domain containing inhibitor of T cell activation 1; immune costimulatory protein B7-H4, B7 superfamily member 1, B7 family member, H4, B7 homolog 4; B7-H4; B7h.5; B7H4; T cell costimulatory molecule B7x, T-cell costimulatory molecule B7x, protein B7S1; PRO1291; VCTN1; B7S1; and B7X. The external Ids for the VTCN1 gene are HGNC:28873; Entrez Gene:79679; Ensembl:ENSG00000134258; OMIM:608162; and UniProtKB:Q7Z7D3;

[0081] WHSC1L1 or NSD3 is known by several different names, including nuclear receptor-binding SET domain protein 3; WHSC1-like 1 isoform 9 with methyltransferase activity to lysine; Wolf-Hirschorn syndrome candidate 1-like 1; histone-lysine N-methyltransferase NSD3; nuclear SET domain-containing protein 3; protein Whistle; EC 2.1.1.43; WHSC1L1; Wolf-Hirschorn syndrome candidate 1-like protein 1; WHSC1-like protein 1; WHISTLE; Pp14328; KMT3F; and KMT3G. The external Ids for the NSD3 gene are HGNC:12767; Entrez Gene:54904; Ensembl:ENSG00000147548; OMIM:607083, and UniProtKB:Q9BZ95.

[0082] ZMYM2 is known by several different names, such as zinc finger MYM type containing 2; zinc finger protein 198; fusion in myeloproliferative disorder protein; zinc finger MYM type protein 2; ZNF198; RAMP; FIM; rearrangement in atypical myeloproliferative disorder protein; rearrangement in atypical myeloproliferative disorder; zinc finger, MYM-type 2; SCLL; and MYM. The external Ids for the ZMYM2 gene are HGNC:12989; Entrez Gene:7750; Ensembl:ENSG00000121741; OMIM:602221, and UniProtKB:Q9UBW7.

[0083] PMEPA1 is known by several different names, such as prostate transmembrane protein, androgen-induced 1; transmembrane, prostate androgen-induced RNA; solid tumor associated 1 protein; protein TMEPAI, TMEPAI; STAG1; prostate transmembrane protein androgen-induced 1; transmembrane prostate androgen-induced protein; and solid tumor associated 1. The external Ids for the PMEPA1 gene are HGNC:14107; Entrez Gene:56937; Ensembl:ENSG00000124225; OMIM:606564, and UniProtKB:Q969W9.

[0084] RAD51 is known by several different names, including, for example, RAD51 recombinase; BRCA1 / BRCA2-containing complex, subunit 5; DNA repair protein RAD51 homolog 1; RAD51 homolog A; HRAD51; RAD51A; RECA; RAD51 homolog (RecA homolog, E. Coli) (S. Cerevisiae); RAD51 (S. Cerevisiae) homolog (E Coli RecA homolog); RAD51 homolog (S. Cerevisiae); RecA, E. Coli, its homolog; recombination protein A; RecA-like protein; HsT16930; HsRad51; HsRAD51; BRCC5; FANCR, and MRMV2. The external Ids for the RAD51 gene are HGNC:9817; Entrez Gene:5888; Ensembl:ENSG00000051180; OMIM:179617; amd UniProtKB:Q06609.

[0085] STMN2 is known by several different names, such as Stathmin2; superior cervical ganglion-10 protein; Stathmin-like 2; Stathmin-2; SCGN10; SCG10; Neuron growth-associated protein (silencer element); superior cervical ganglion, neuron-specific 10; Neuron-specific growth-associated protein; and protein SCG10. External Ids for the STMN2 gene are HGNC:10577; Entrez Gene:11075; Ensembl:ENSG00000104435; OMIM:600621, and UniProtKB:Q93045.

[0086] Various NRG1 fusion genes have been described in Dhanasekaran et al. Nature Communications 5:5893, 2014 and in Jonna et al., Clin Cancer Res 8 / 15 2019, 25(16)4966-4972.

[0087] The invention further provides a bispecific antibody comprising a first antigen binding site that binds an extracellular portion of ErbB-2 and a second antigen binding site that binds an extracellular portion of ErbB-3 for use in treating a subject at risk of having an ErbB-2 and ErbB-3 positive cancer, wherein cells of the cancer comprise an NRG1 fusion gene comprising at least a portion of the NRG1 gene fused to sequences from different chromosomal locations, and the subject is a pre-treated cancer subject that has received prior ErbB-1; ErbB-2 or ErbB-3 targeted tumor therapy.

[0088] Further provided is a method of treating a subject at risk of having ErbB-2 and ErbB-3 positive cancer, wherein cells of the cancer comprise an NRG1 fusion gene comprising at least a portion of the NRG1 gene fused to a sequence from a different chromosomal location, and the subject is a pre-treated cancer subject that has undergone prior chemotherapy or tumor therapy targeted to ErbB-2 or ErbB-3, the method comprising administering to a subject in need thereof a bispecific antibody comprising a first antigen binding site that binds an extracellular portion of ErbB-2 and a second antigen binding site that binds an extracellular portion of ErbB-3.

[0089] A subject is at risk of having the above-mentioned cancers when the subject is in remission of the cancer as a result of chemotherapy, treatment with ErbB-1;ErbB-2 or ErbB-3 targeted tumor therapy. Such subjects may be prophylactically treated with a bispecific antibody according to the invention.

[0090] Chemotherapy according to the present invention preferably comprises gemcitabine, capecitabine, carboplatin, a taxane such as docetaxel or paclitaxel, 5-fluorouracil (with or without radiotherapy), vinorelbine, mitoxantrone, vinblastine, cisplatin (or pemetrexed), oxaliplatin, carboplatin, ifosfamide, mitomycin C, vindesine, etoposide, Folfox (i.e. a combination of 5-fluorouracil, leucovorin, and oxaliplatin) or Folfiri (i.e. a combination of leucovorin, 5-fluorouracil and irinotecan), Folfirinox (a combination of leucovorin, 5-fluorouracil, irinotecan and oxaliplatin) or any combination thereof.

[0091] In a preferred embodiment, chemotherapy comprises gemcitabine, capecitabine, 5-fluorouracil (alone or in combination with radiation therapy), Folfirinox, gemcitabine in combination with albumin-bound paclitaxel, gemcitabine in combination with erlotinib for subjects diagnosed with pancreatic cancer, preferably pancreatic ductal adenocarcinoma (PDAC).

[0092] In a preferred embodiment, chemotherapy includes gemcitabine in combination with a platinum analogue (such as cisplatin, oxaliplatin and / or carboplatin), taxanes (such as paclitaxel or docetaxel) in combination with a platinum analogue (such as cisplatin, oxaliplatin and / or carboplatin), pemetrexed in combination with a platinum analogue (such as cisplatin, oxaliplatin and / or carboplatin), ifosfamide, mytomycine C, vindesine, vinblastine, etoposide and / or vinorelbine for subjects diagnosed with lung cancer, preferably non-small cell lung cancer (NSCLC). The chemotherapy for a subject diagnosed with lung cancer, preferably non-small cell lung cancer (NSCLC), may be combined with anti-EGFR drugs (such as erlotinib or cetuximab), anti-vascular endothelial growth factor therapy, VEGF traps such as bevacizumab and / or ziv-aflibercept.

[0093] Preferably, chemotherapy comprises or consists of a combination of Gemcitabine and Capecitabine and / or Folfiri in the treatment of pancreatic cancer, such as pancreatic adenocarcinoma or hepatoma, including metastases to the liver. The cells of the cancer preferably contain the NRG1 gene fused to ATP1B1. Administration of the bispecific antibody of the invention comprises a biweekly dose of 750 mg antibody.

[0094] Preferably, chemotherapy comprises or consists of a combination of carboplatin and pemextred, preferably administered in combination with pembrolizumab in the treatment of lung cancer, preferably lung adenocarcinoma. The cells of the cancer preferably contain the NRG1 gene fused to CD74. Administration of the bispecific antibody of the invention comprises a biweekly dose of 750 mg antibody.

[0095] Preferably, chemotherapy comprises or consists of a combination of gemcitabine and capecitabine in the treatment of pancreatic adenocarcinoma. The combination of gemcitabine and capecitabine is preferably followed by administration of Folfiri before the bispecific antibody of the invention is administered. The cells of the cancer preferably contain the NRG1 gene fused to CD74. Administration of the bispecific antibody of the invention comprises a biweekly dose of 750 mg antibody.

[0096] The antigen-binding site in an antibody is typically located in the variable domain, which contains a heavy chain variable region and a light chain variable region.

[0097] The subject has preferably undergone chemotherapy or therapy targeted at ErbB-2 inhibition. Inhibition of ErbB-2 signaling, also referred to as ErbB-2 targeted tumor therapy, preferably comprises administration of a monospecific bivalent antibody comprising an antigen binding site that binds the extracellular portion of ErbB-2; or a tyrosine kinase inhibitor (TKI) of ErbB-2 or a combination thereof, the monospecific bivalent antibody being preferably trastuzumab, pertuzumab, or trastuzumab-emtansine, and inhibiting ErbB-2. The TKI is preferably lapatinib, canertinib, neratinib, tucatinib (irbinitinib), CP-724714, taloxitinib, mubritinib, afatinib, balitinib, and dacomitinib, preferably one or more of lapatinib, canertinib, neratinib, tucatinib (irbinitinib), mubritinib, afatinib, balitinib, or dacomitinib, more preferably afatinib.

[0098] The therapeutic method or bispecific antibody for use in the treatment described in the present invention preferably further determines whether the cells contain NRG1 fusions or whether the tumor contains cells with NRG1 fusions. This can be done, for example, with cells from a biopsy. Various methods are available, many known in the art. It is known that the region where chromosomal breaks occur in the case of NRG1 fusions is routine for the skilled artisan to determine whether the tumor contains such an NRG1 fusion. One method is by PCR amplification with primers that span the junction of the NRG1 fusion. This can be easily performed for NRG1 fusions that are known to occur. New fusions can also be easily detected. A suitable method is, for example, by junction cloning techniques used to find binding sites of retroviral genomes. A suitable method is by LAM-PCR, see Schmidt et al Nature Methods 4,1051-1057(2007)doi:10.1038 / nmeth1103 and specific references therein to LAM techniques.

[0099] Available techniques for identifying putative NRG1 fusions include RNA-based methodologies including anchored multiplex PCR, nCounter, RT-PCR, transcriptome analysis, DNA-based methodologies including FISH, hybrid capture-based next-generation sequencing (NGS), and amplicon-based NGS, among other commercially available techniques.

[0100] Various methods are available for determining the levels of ErbB receptors on the cells of a cancer. Examples are immunohistochemistry or fluorescent in situ hybridization. HercepTest™ and / or HER2 FISH (pharm Dx®) marketed by Monogram Biosciences, both marketed by Dako Denmark A / S and / or using the HERmark® assay, are examples of suitable assays for determining ErbB-2 or ErbB-3 cell surface receptor density. Other methods for determining ErbB-2 receptor cell density are well known to those skilled in the art. In vivo methods for determining ErbB-2 are also known, see for example Chernomoridik et al. Mol Imaging. 2010 Aug;9(4):192-200, and Ardeshirpour et al. Technol Cancer Res Treat. 2014 Oct;13(5):427-434. Preferably, the methods disclosed herein further comprise determining ErbB-2 cell surface receptor density for the cells or tumor. Such methods are known to those of skill in the art (see, e.g., van der Woning and van Zoelen Biochem Biophys Res Commun. 2009 Jan 9;378(2):285-9). Preferably, the methods disclosed herein further comprise determining ErbB-1 cell surface receptor density for the cells or tumor. Such methods are known to those of skill in the art (see, e.g., EGFR pharmDx™ kit (Dako) amd McDonagh et al. Mol Cancer Ther 2012;11:582). Similar methods can be used to determine ErbB-4 cell surface receptor density. In some embodiments, ErbB-1, ErbB-2, ErbB-3, and ErbB-4 cell surface receptor densities are determined by FACS analysis on biopsied tumor cells.

[0101] The amount of bispecific antibody to be administered to a subject typically falls within the therapeutic window, meaning that a sufficient amount is used to obtain a therapeutic effect, but does not exceed a threshold that leads to an unacceptable degree of side effects. The smaller the amount of antibody required to obtain a desired therapeutic effect, the larger the therapeutic window will typically be. The selected dosage level depends on a variety of factors, including the route of administration, the time of administration, the rate of excretion of the particular compound employed, the duration of treatment, other drugs, compounds and / or materials used in combination, the age, sex, weight, condition, general health and medical history of the subject being treated, and similar factors well known in the medical arts. The dosage can be within or below the range of the administration regimen for nivolumab.

[0102] Regarding the bispecific antibody of the present invention, it has a good safety profile at relatively high doses, thus providing a large therapeutic window, making it a good partner for combination therapy. The administration of the bispecific antibody of the present invention follows a dosing regimen of 750 mg every week, every other week, or every three weeks, preferably 750 mg every other week or every three weeks. The administration is preferably in subjects suffering from pancreatic cancer, NSCLC, or solid tumors, including any subject with a solid tumor with NRG1 fusion, such subject progressing with chemotherapy or administration of ErbB-2 or ErbB-3 targeting drugs or TKIs. Alternatively, the dosing regimen is followed by including weekly administration of a fixed dose of 400 mg, preferably starting after a single dose of 800 mg. Following this alternative dosing regimen, the bispecific antibody of the present invention is preferably administered at a weekly dose of 400 mg for three weeks, followed by one week without administration. This is then followed by one or more cycles of four week duration consisting of a weekly constant dose of 400 mg followed by one week without administration, preferably until a therapeutic effect is observed.

[0103] Administration preferably involves intravenous injection consisting of two infusions of the bispecific antibody of the invention to reach the full dose, preferably when administering more than 360 mg of antibody. Alternatively, a single infusion consisting of the full dose may be given for lower doses, for example when administering 360 mg or less of antibody. Premedication may possibly be included in the dosing regimen to mitigate infusion-related reactions.

[0104] In a preferred embodiment, the treatment comprises the administration of a bispecific antibody to a subject with NSCLC, preferably metastatic disease in the lung and pleura, and cancer cells with an SDC4-NRG1 fusion with a first antigen-binding site that binds the extracellular portion of ErbB-2 and a second antigen-binding site that binds the extracellular portion of ErbB-3 in a patient who has received afatinib pretreatment. Preferably, the treatment comprises stabilization of the tumor in terms of size or lesions, including reduction of the tumor, or prevention of further tumor growth. Preferably, the treatment or administration is with a bispecific antibody according to the invention on a weekly regimen, proceeding for a period of at least 1, 2, 4, 8 or at least 12 months. Preferably, a dosing regimen is followed that comprises a weekly cycle starting with an initial dose of 800 mg followed by a flat dose of 400 mg every week. From the third week, the bispecific antibody of the invention is given at a weekly dose of 400 mg for three weeks, followed by one week without administration of the bispecific antibody of the invention. Alternatively, a dosing regimen includes a 2-week cycle beginning with an initial administration of 750 mg infusion over a 4-hour period followed by a flat dose of 750 mg, followed by a 2-hour infusion of 750 mg every other week for a 4-week cycle. A further alternative includes administration of a flat dose of 750 mg per subject every 3 weeks.

[0105] Preferably, the diagnosis involves molecular profiling using targeted sequencing, analysis of one or more biomarkers, including fusions, insertions / deletions (indels), single nucleotide variants and / or copy number variations. Preferably, the tumor genome shows no mutations in one or more genes selected from the group consisting of EGFR, KRAS, cKIT-BRCA1-2, MET, ROS, RET, ALK.

[0106] Preferably, disease progression includes measuring antitumor activity in the lungs by using CT scans and determining the objective complete response rate (ORR), duration of response (DOR), progression-free survival (PFS) and survival rate as assessed by RECIST version 1.1. Preferably, the bispecific antibody, having a first antigen-binding site that binds the extracellular portion of ErbB-2 and a second antigen-binding site that binds the extracellular portion of ErbB-3, in particular MF3958xMF3178, stabilizes the tumor in terms of size or pathology or the treatment prevents further tumor growth. Preferably, the treatment has a good safety profile with no drug-related toxicity or limited occurrence of grade 3-5 adverse events that are actual or suspected to be drug-related.

[0107] Bispecific antibodies can be formulated as pharmaceutical compositions comprising a pharma- ceutical acceptable carrier, diluent, or excipient, and any additional active agents. Antibodies and compositions comprising antibodies can be administered by any route, including parenteral, enteral, and topical. Parenteral administration is usually by injection, and includes, for example, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracerebrospinal, intratumoral, and intrasternal injection and infusion.

[0108] The present disclosure provides bispecific antibodies for use in the methods and treatments described herein. A suitable bispecific antibody comprises a first antigen-binding site that binds ErbB-2 and a second antigen-binding site that binds ErbB-3. The bispecific antibody reduces the ligand-induced receptor function of ErbB-3 on ErbB-2 and ErbB-3 positive cells and / or disrupts ErbB-2 and ErbB-3 heterodimerization, or can do so. Preferred antibodies and their preparation are disclosed in WO 2015 / 130173, which is incorporated herein by reference. The examples in WO 2015 / 130173 further describe some properties of the antibodies, such as ligand binding and epitope mapping.

[0109] As used herein, the terms "subject" and "patient" are used interchangeably and refer to a mammal, such as a human, mouse, rat, hamster, guinea pig, rabbit, cat, dog, monkey, cow, horse, pig, etc. (e.g., a patient suffering from cancer, such as a human patient).

[0110] As used herein, the terms "treat," "treating," and "treatment" refer to any type of intervention or process in which an active agent or combination of active agents is administered to a subject for the purpose of curing or ameliorating a disease or its symptoms, including reversing, alleviating, ameliorating, inhibiting, or slowing symptoms, complications, conditions, or biochemical indicators associated with a disease, as well as preventing the onset, progression, development, severity, or recurrence of symptoms, complications, conditions, or biochemical indicators associated with a disease.

[0111] As used herein, "effective treatment" or "positive therapeutic response" refers to a treatment that results in a beneficial effect, e.g., amelioration of at least one symptom of a disease or disorder, such as cancer. A beneficial effect can result in an improved state beyond a baseline, such as an improvement beyond a measurement or observation made prior to the initiation of therapy by the method. A beneficial effect can result in a state that slows, stabilizes, stops, or reverses the progression of cancer in a subject at any clinical stage, as evidenced, for example, by a reduction or elimination of clinical or diagnostic symptoms of the disease, or a reduction or elimination of markers of cancer. An effective treatment can, for example, reduce tumor size, reduce the presence of circulating tumor cells, reduce or prevent metastasis of tumors, slow or prevent tumor growth, and / or prevent or delay tumor recurrence or relapse.

[0112] The term "therapeutic amount" or "effective amount" refers to an amount of an agent or combination of agents that provides a desired biological, therapeutic, and / or prophylactic result. The result may be reduction, amelioration, remission, reduction, delay, and / or alleviation of one or more signs, symptoms, or causes of a disease, or other desired change in biology. In some embodiments, a therapeutic amount is an amount sufficient to delay the progression of a tumor. In some embodiments, a therapeutic amount is an amount sufficient to prevent or delay the recurrence of a tumor.

[0113] A therapeutic amount of a drug or composition may (i) reduce the number of cancer cells; (ii) reduce the size of a tumor; (iii) inhibit, prevent, slow or stop to some extent cancer cell invasion into peripheral organs; (iv) inhibit tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay the development and / or recurrence of tumors; and / or (vii) relieve to some extent one or more symptoms associated with cancer.

[0114] Therapeutic amounts can vary depending on factors such as the disease state, age, sex, and weight of the individual being treated, and the ability of the agent or combination of agents to elicit a desired response in the individual. Therapeutic amounts can be administered in one or more administrations. Therapeutic amounts also include an amount that balances any toxic or detrimental effects of the agent or combination of agents with the therapeutically beneficial effects.

[0115] As used herein, the term "antigen-binding site" refers to a site derived from, and preferably present in, a bispecific antibody capable of binding to an antigen. An antigen-binding site is typically formed by and present in the variable domains of an antibody. The variable domain contains said antigen-binding site. A variable domain that binds to an antigen is a variable domain that comprises an antigen-binding site that binds to an antigen.

[0116] In one embodiment, an antibody variable domain comprises a heavy chain variable region (VH) and a light chain variable region (VL). The antigen binding site may be present in the combined VH / VL variable domain, or in the VH region alone, or in the VL region alone. If the antigen binding site is present in only one of the two regions of the variable domain, the corresponding variable region may contribute to the folding and / or stability of the combined variable region, but does not contribute significantly to the binding of the antigen itself.

[0117] As used herein, antigen binding refers to the typical binding ability of an antibody to its antigen.An antibody that contains an antigen binding site that binds to ErbB-2 binds to ErbB-2 and otherwise binds to the homologous receptors ErbB-1 and ErbB-4 of the same species at least 100-fold less under identical conditions.An antibody that contains an antigen binding site that binds to ErbB-3 binds to ErbB-3 and otherwise does not bind to the homologous receptors ErbB-1 and ErbB-4 of the same species under identical conditions.

[0118] Considering that ErbB family is a family of cell surface receptors, binding is typically evaluated in cells expressing the receptor(s). The binding of antibody to antigen can be evaluated in various ways. One method is to incubate antibody with antigen (preferably, cells expressing antigen), remove unbound antibody (preferably, by washing step), and detect bound antibody by labeled antibody that binds to bound antibody.

[0119] Antigen binding by an antibody is typically mediated through a specific three-dimensional structure of both the complementary region and the antigen and variable domains of the antibody, allowing these two structures to bind together precisely (an interaction similar to a lock and key) as opposed to the random, non-specific adhesion of the antibody. Since an antibody typically recognizes an epitope of an antigen, and such epitopes may be present in other compounds as well, an antibody according to the invention that binds ErbB-2 and / or ErbB-3 may recognize other proteins as well, if such other compounds contain the same epitope. Thus, the term "binding" does not exclude the binding of the antibody to another protein or proteins that contain the same epitope. Such other protein(s) are preferably not human proteins. The ErbB-2 antigen-binding site and the ErbB-3 antigen-binding site as defined herein typically do not bind to other proteins on the membrane of cells after birth, preferably in adult humans. Bispecific antibodies disclosed herein are typically capable of binding ErbB-2 and ErbB-3 with a binding affinity of at least 1×10e-6 M.

[0120] The term "interferes with binding" as used herein means that an antibody is directed to an epitope on ErbB-3 and that the antibody competes with a ligand for binding to ErbB-3. The antibody may reduce ligand binding, displace the ligand when it is already bound to ErbB-3, or at least partially prevent the ligand from being able to bind to ErbB-3, for example through steric hindrance.

[0121] As used herein, the term "antibody" preferably refers to a protein molecule belonging to the immunoglobulin class of proteins that contains one or more variable domains that bind to an epitope on an antigen, such domains being derived from or sharing sequence homology with the variable domains of an antibody. Therapeutic antibodies are preferably as close as possible to the natural antibodies of the subject to be treated (e.g., human antibodies in the case of a human subject). Antibody binding can be expressed in terms of specificity and affinity. Specificity determines which antigen or its epitope is specifically bound by a binding domain. Affinity is a measure of the strength of binding to a particular antigen or epitope. Typically, antibodies for therapeutic use have an affinity of up to 1x10e-10M or higher. Antibodies such as bispecific antibodies of the present invention comprise the constant domains (Fc portion) of natural antibodies. The antibodies of the present invention are typically bispecific full-length antibodies, preferably of human IgG subclass. Preferably, the antibodies disclosed herein are of the human IgG1 subclass. Such antibodies have good ADCC properties, favorable half-lives upon in vivo administration to humans, and CH3 engineering techniques exist that can prepare modified heavy chains that preferentially form heterodimers over homodimers upon co-expression in clonal cells.

[0122] The antibodies disclosed in the present invention are preferably "full-length" antibodies. The term "full-length antibody" is defined as including an essentially complete antibody, but not necessarily having all the functions of an intact antibody. For the avoidance of doubt, a full-length antibody comprises two heavy chains and two light chains. Each chain contains a constant (C) and a variable (V) region, which can be broken down into domains called CH1, CH2, CH3, VH, and CL, VL (the appropriate amino acid sequences of each domain are shown in Figures 1 and 2). Antibodies bind to antigens via the variable domains contained in the Fab portion, and after binding, can interact with molecules and cells of the immune system via the constant domains, primarily the Fc portion. The terms "variable domain", "VH / VL pair", and "VH / VL" are used interchangeably herein. Full-length antibodies according to the present invention encompass antibodies in which there may be mutations that provide desired properties. Such mutations should not be deletions of substantial portions of any of the regions. However, antibodies in which one or several amino acid residues are deleted without essentially altering the binding properties of the resulting antibody are included in the term "full-length antibody". For example, an IgG antibody can have an insertion, deletion, or combination of 1 to 20 amino acid residues in the constant region. For example, the ADCC activity of an antibody can be improved by slightly modifying the constant region of the antibody when the antibody itself has low ADCC activity (see Junttila, TT, K. Parsons, et al. (2010). "Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer." Cancer Research 70(11):4481-4489).

[0123] Full-length IgG antibodies are preferred due to their favorable half-life and the need to remain close to the complete autologous (human) molecule for immunogenicity reasons. The antibodies disclosed herein are preferably bispecific IgG antibodies, preferably bispecific full-length IgG1 antibodies. IgG1 is preferred due to its long circulating half-life in humans. To prevent any immunogenicity in humans, it is preferred that the bispecific IgG antibody is human IgG1.

[0124] The term "bispecific (bs)" means that one part of an antibody (as defined above) binds to one epitope on an antigen, while a second part binds to a different epitope. The different epitopes are typically present on different antigens. The heavy chain variable regions of a bispecific antibody are typically different from each other, whereas the light chain variable regions are preferably the same. Bispecific antibodies in which different heavy chain variable regions bind to the same or a common light chain are also called bispecific antibodies with a common light chain. Bispecific antibodies described herein typically comprise one variable domain that binds ErbB-2 and another variable domain that binds ErbB-3.

[0125] A preferred bispecific antibody can be obtained by co-expression of two different heavy chains and a common light chain in a single cell. If a wild-type CH3 domain is used, co-expression of two different heavy chains and a common light chain will result in three different species AA, AB and BB. To increase the proportion of the desired bispecific product (AB), CH3 genetic engineering can be used, or in other words, heavy chains with compatible heterodimerization domains can be used, as defined below. Suitable compatible CH3 heterodimerization domains are shown in Figures 2d and 2e.

[0126] As used herein, the term "compatible heterodimerization domain" refers to a protein domain that has been engineered such that engineered domain A' preferentially forms heterodimers with engineered domain B', and vice versa, while homodimerization between A'-A' and B'-B' is reduced.

[0127] The term "common light chain" refers to a light chain that may be identical or may have some amino acid sequence differences, while the binding specificity of the full-length antibody is not affected. For example, by introducing and testing conservative amino acid changes, amino acid changes in regions that do not contribute or only partially contribute to the binding specificity when paired with the heavy chain, etc., light chains that are not identical but are still functionally equivalent can be prepared or found. The terms "common light chain", "common VL", "single light chain", and "single VL", with or without the addition of the term "rearranged", are all used interchangeably herein.

[0128] The common light chain (variable region) preferably has a germline sequence. Preferred germline sequences are light chain variable regions that are frequently used in the human repertoire and have good thermodynamic stability, yield, and solubility. In a preferred embodiment, the light chain is a light chain variable region of IgVκ1-39 as shown in sequence 1C "Common light chain IGKV1-39 / jk1" having 0-10, preferably 0-5, amino acid insertions, deletions, substitutions, additions, or combinations thereof. *The IgVkappa 1-39 light chain region comprises the amino acid sequence of the IgVkappa 1-39 gene segment. IgVkappa 1-39 is short for immunoglobulin variable kappa 1-39 gene. This gene is also immunoglobulin kappa variable 1-39, IGKV139; or IGKV1-39. The external Ids for this gene are HGNC:5740, Entrez Gene:28930; Ensembl:ENSG00000242371. The variable regions of IGKV1-39 are listed in FIG. 1. The V region can be combined with one of five J regions. FIG. 1 illustrates two preferred sequences for IgVkappa 1-39 combined with a J region. The combined sequences are shown as IGKV1-39 / jk1 and IGKV1-39 / jk5, with alternative names being IgVkappa 1-39 / jk1 and IGKV1-39 / jk5. * 01 / IGJκ1 * 01 or IgVκ1-39 * 01 / IGJκ5 * 01 (nomenclature according to the IMGT database at imgt.org on the World Wide Web).

[0129] IgVκ1-39 containing the light chain variable region * Preferably, 01 is a germline sequence. * 01 or / IGJκ5 * It is further preferred that 01 is a germline sequence. In a preferred embodiment, the IGKV1-39 / jk1 or IGKV1-39 / jk5 light chain variable region is a germline sequence.

[0130] In a preferred embodiment, the light chain variable region is selected from the group consisting of germline IgVκ1-39 * In a preferred embodiment, the light chain variable region comprises the kappa light chain IgVκ1-39 * 01 / IGJκ1 * 01 or IgVκ1-39 * 01 / IGJκ5 * In a preferred embodiment, IgVκ1-39 * 01 / IGJκ1 * 01. The light chain variable region is preferably the germline kappa light chain IgVκ1-39 *01 / IGJκ1 * 01 or germline kappa light chain IgVκ1-39 * 01 / IGJκ5 * 01, preferably germline IgVκ1-39 * 01 / IGJκ1 * Including 01.

[0131] Obviously, one skilled in the art will recognize that "common" refers to functional equivalents of light chains that are not identical in amino acid sequence. Many variants of the light chain exist, and there are mutations (deletions, substitutions, additions) that do not substantially affect the formation of a functional binding region. The light chain can also be a light chain with insertions, deletions, substitutions, additions, or combinations thereof of 1 to 5 amino acids as specified herein above.

[0132] Preferably, both the first antigen-binding site and the second antigen-binding site comprise a light chain variable region comprising a CDR1 having the sequence (RASQSISSYLN), a CDR2 having the sequence (AASSLQS), and a CDR3 having the sequence (QQSYSTPPT).

[0133] The antibodies disclosed herein can reduce the ligand-induced receptor function of ErbB-3 on ErbB-2 and ErbB-3 positive cells. In the presence of excess ErbB-2, the ErbB-2 / ErbB-3 heterodimer can provide a growth signal to expressing cells in the absence of a detectable ligand for the ErbB-3 chain in the heterodimer. This ErbB-3 receptor function is referred to herein as the ligand-independent receptor function of ErbB-3. The ErbB-2 / ErbB-3 heterodimer also provides a growth signal to expressing cells in the presence of an ErbB-3 ligand. This ErbB-3 receptor function is referred to herein as the ligand-induced receptor function of ErbB-3.

[0134] As used herein, the term "ErbB-3 ligand" refers to a polypeptide that binds and activates ErbB-3. Examples of ErbB-3 ligands include, but are not limited to, neuregulin 1 (NRG) and neuregulin 2, betacellulin, heparin-binding epidermal growth factor, and epiregulin. The term includes biologically active fragments and / or variants of naturally occurring polypeptides.

[0135] Preferably, the ligand-induced receptor function of ErbB-3 is ErbB-3 ligand-induced growth of ErbB-2 and ErbB-3 positive cells. In a preferred embodiment, the cells are MCF-7 cells (ATCC® HTB-22™); SKBR3 (ATCC® HTB-30™) cells; NCI-87 (ATCC® CRL-5822™) cells; BxPC-3-luc2 cells (Perkin Elmer 125058), BT-474 cells (ATCC® HTB-20™) or JIMT 1 cells (DSMZ number: ACC589).

[0136] As used herein, ligand-induced receptor function is reduced by at least 20%, preferably at least 30, 40, 50 60, or at least 70%, and in particularly preferred embodiments, ligand-induced receptor function is reduced by 80, more preferably 90%. This reduction is preferably determined by determining ligand-induced receptor function in the presence of a bispecific antibody disclosed herein and comparing it to the same function under otherwise identical conditions in the absence of the antibody. The conditions include the presence of at least an ErbB-3 ligand. The amount of ligand present is preferably an amount that induces half-maximal growth of ErbB-2 and ErbB-3 positive cell lines. The ErbB-2 and ErbB-3 positive cell lines for this test are preferably MCF-7 cell line (ATCC® HTB-22™), SKBR3 cell line (ATCC® HTB-30™), JIMT 1 cell line (DSMZ ACC 589) or NCI-87 cell line (ATCC® CRL-5822™). The test for determining ErbB-3 ligand induced receptor function and / or ligand is preferably the test for ErbB-3 ligand induced growth reduction as specified in the examples.

[0137] The ErbB-2 protein contains several domains (see Figure 1 in Landgraf, R Breast Cancer Res. 2007;9(1):202-). The extracellular domains are referred to as domains I-IV. The binding locations of the antigen binding sites of the antibodies described herein to each domain have been previously mapped. Bispecific antibodies having an antigen binding site (first antigen binding site) that binds domain I or domain IV of ErbB-2 (first antigen binding site) contain heavy chain variable regions that maintain significant binding specificity and affinity for ErbB-2 when combined with various light chains. Bispecific antibodies having an antigen binding site (first antigen binding site) that binds domain I or domain IV of ErbB-2 (first antigen binding site) and an antigen binding site for ErbB-3 (second antigen binding site) are more effective at reducing ligand-induced receptor function of ErbB-3 when compared to bispecific antibodies that contain an antigen binding site (first antigen binding site) that binds another extracellular domain of ErbB-2. Preferred are bispecific antibodies comprising an antigen-binding site (first antigen-binding site) that binds ErbB-2, where the antigen-binding site binds to domain I or domain IV of ErbB-2. Preferably, the antigen-binding site binds to domain IV of ErbB-2. Preferred antibodies comprise a first antigen-binding site that binds domain I of ErbB-2 and a second antigen-binding site that binds domain III of ErbB-3.

[0138] In one preferred embodiment, the antibody comprises an antigen binding site that binds at least one amino acid in Domain I of ErbB-2 selected from the group consisting of T144, T164, R166, P172, G179, S180, and R181, and a surface exposed amino acid residue located within about 5 amino acid positions of T144, T164, R166, P172, G179, S180, or R181.

[0139] In one preferred embodiment, the antibody preferably comprises an antigen-binding site that binds at least one amino acid in domain III of ErbB-3 selected from the group consisting of R426 and a surface-exposed amino acid residue located within 11.2A of R426 in native ErbB-3.

[0140] Bispecific antibodies that bind ErbB-2 and have an antigen-binding site (first antigen-binding site) that further comprises ADCC are more effective than other ErbB-2 binding antibodies that did not have significant ADCC activity, especially in vivo. Therefore, bispecific antibodies that exhibit ADCC are preferred. Antibodies whose first antigen-binding site binds to domain IV of ErbB-2 have been found to have intrinsic ADCC activity. Domain I-binding ErbB-2 binding antibodies with low intrinsic ADCC activity can be engineered to enhance the ADCC-active Fc region to mediate antibody function by binding to different receptors on immune effector cells such as macrophages, natural killer cells, B cells, and neutrophils. Some of these receptors, such as CD16A (FcγRIIIA) and CD32A (FcγRIIA), activate cells to mount a response to antigens. Other receptors, such as CD32B, inhibit the activation of immune cells. By engineering the Fc region (by introducing amino acid substitutions) to bind activating receptors with higher selectivity, antibodies can be made with greater ability to mediate the cytotoxic activity desired by anti-cancer Mabs. One technique for enhancing ADCC of antibodies is afucosylation. (See Junttila, TT, K. Parsons, et al. (2010). "Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer." Cancer Research 70(11):4481-4489). Thus, afucosylated bispecific antibodies as disclosed in the present invention are further provided. Alternatively or in addition, multiple other strategies can be used to achieve ADCC enhancement, including, for example, glycoengineering and mutagenesis, all of which seek to improve Fc binding to low affinity activating FcγRIIIa and / or reduce binding to low affinity inhibitory FcγRIIb.

[0141] There are several in vitro methods to determine the effectiveness of antibodies or effector cells in inducing ADCC. These include, among others, the chromium-51 [Cr51] release assay, the europium [Eu] release assay, and the sulfur-35 [S35] release assay. Typically, a labeled target cell line expressing a particular surface-exposed antigen is incubated with an antibody specific for that antigen. After washing, effector cells expressing the Fc receptor CD16 are typically incubated with the antibody-labeled target cells. Target cell lysis is then measured by the release of intracellular label, typically by scintillation counter or spectrophotometry.

[0142] In a preferred bispecific antibody, the affinity of the second antigen-binding site for ErbB3-positive cells is equal to or preferably higher than the affinity of the first antigen-binding site for ErbB-2-positive cells. The affinity (KD) of the second antigen-binding site for ErbB-3-positive cells is preferably 2.0 nM or less, more preferably 1.5 nM or less, more preferably 1.39 nM or less, more preferably 0.99 nM or less. In a preferred embodiment, the affinity of the second antigen-binding site for ErbB-3 on SK BR 3 cells is 2.0 nM or less, more preferably 1.5 nM or less, more preferably 1.39 nM or less, preferably 0.99 nM or less. In one embodiment, the affinity is in the range of 1.39 to 0.59 nM. In a preferred embodiment, the affinity of the second antigen-binding site for ErbB-3 on BT 474 cells is 2.0 nM or less, more preferably 1.5 nM or less, more preferably 1.0 nM or less, more preferably less than 0.5 nM, more preferably 0.31 nM or less, more preferably 0.23 nM or less. In one embodiment, the affinity (KD) is in the range of 0.31 to 0.15 nM. The above-mentioned affinity is preferably measured using steady-state cell affinity measurements as described in the Examples of WO 2015 / 130173, where cells are incubated at 4°C with a radiolabeled antibody and then cell-bound radioactivity is measured.

[0143] The affinity (KD) of the first antigen-binding site for ErbB-2 positive cells is preferably 5.0 nM or less, more preferably 4.5 nM or less, more preferably 3.9 nM or less. In a preferred embodiment, the affinity of the first antigen-binding site for ErbB-2 on SK BR 3 cells is 5.0 nM or less, preferably 4.5 nM or less, more preferably 4.0 nM or less, more preferably 3.5 nM or less, more preferably 3.0 nM or less, more preferably 2.3 nM or less. In one embodiment, the affinity is in the range of 3.0 to 1.6 nM. In one preferred embodiment, the affinity of the first antigen-binding site for ErbB-2 on BT474 cells is 5.0 nM or less, preferably 4.5 nM or less, more preferably 3.9 nM or less. In one embodiment, the affinity is in the range of 4.5 to 3.3 nM. The above mentioned affinities are preferably measured using steady state cell affinity measurements as described in the examples of WO 2015 / 130173, in which cells are incubated at 4°C with radiolabelled antibodies and then cell-bound radioactivity is measured.

[0144] Preferably, the bispecific antibodies used in the disclosed methods do not significantly affect cardiomyocyte survival. Cardiotoxicity is a known risk factor in ErbB-2 targeting therapy, and complications become more frequent when trastuzumab is combined with anthracyclines, thereby inducing cardiac stress.

[0145] The bispecific antibodies disclosed herein are preferably used in humans, and therefore the preferred antibodies are human or humanized antibodies. Human tolerance to a polypeptide is governed by many different aspects. Immunity may be T-cell mediated, B-cell mediated or otherwise mediated, and is one of the variables involved in human tolerance to a polypeptide. The constant region of the bispecific antibody is preferably a human constant region. This constant region may contain one or more, preferably no more than 10, preferably no more than 5 amino acids different from the constant region of a naturally occurring human antibody. The constant portion is preferably derived entirely from a naturally occurring human antibody. The various antibodies produced herein are derived from a human antibody variable domain library. These variable domains are therefore human. The unique CDR regions may be of human origin, synthetic or derived from another organism. This variable region is considered a human variable region if it has an amino acid sequence that is identical to the amino acid sequence of the variable region of a naturally occurring human antibody, except for the CDR regions. The variable region of the ErbB-2 binding VH, ErbB-3 binding VH, or light chain of the antibody may contain one or more, preferably no more than 10, preferably no more than 5, amino acids that differ from the variable regions of naturally occurring human antibodies, not counting possible differences in the amino acid sequences of the CDR regions. Such mutations also arise inherently in the context of somatic hypermutation.

[0146] Antibodies can be derived from various animal species, at least for the heavy chain variable region. For example, it is common practice to humanize murine heavy chain variable regions. There are various ways in which this can be achieved, including CDR grafting to a human heavy chain variable region with a 3-D structure that matches that of the mouse heavy chain variable region; deimmunization of the mouse heavy chain variable region, which is preferably performed by removing known or suspected T-cell or B-cell epitopes from the mouse heavy chain variable region. Removal is typically by replacing one or more amino acids in the epitope with another (typically conservative) amino acid, such that the sequence of the epitope is modified so that it is no longer a T-cell or B-cell epitope.

[0147] Such deimmunized mouse heavy chain variable regions are less immunogenic in humans than the original mouse heavy chain variable regions. Preferably, the variable regions or domains are further humanized, e.g., veneering. By using veneering techniques, exterior residues that are easily encountered by the immune system are selectively replaced with human residues to provide hybrid molecules that contain either a weakly immunogenic or a substantially non-immunogenic veneered surface. The animals used in the present invention are preferably mammals, more preferably primates, and most preferably humans.

[0148] The bispecific antibodies disclosed herein preferably comprise the constant region of a human antibody. According to differences in their heavy chain constant domains, antibodies are classified into five classes, or isotypes: IgG, IgA, IgM, IgD, and IgE. These classes or isotypes comprise at least one of the heavy chains named by the corresponding Greek letter. Preferably, the constant region comprises an IgG constant region, more preferably an IgG1 constant region, preferably a mutated IgG1 constant region. Some changes in the constant region of IgG1 are natural and / or tolerated without altering the immunological properties of the resulting antibody, such as, for example, allotypes G1m1, 17, and G1m3. Typically, about 1-10 amino acid insertions, deletions, substitutions, or combinations thereof are tolerated in the constant region.

[0149] Preferred bispecific antibodies as disclosed herein include: - at least the CDR3 sequence, preferably at least the CDR1, CDR2 and CDR3 sequences, of an ErbB2 specific heavy chain variable region selected from the group consisting of MF2926, MF2930, MF1849, MF2973, MF3004, MF3958, MF2971, MF3025, MF2916, MF3991, MF3031, MF2889, MF2913, MF1847, MF3001, MF3003 and MF1898, or a heavy chain variable region sequence which differs from the listed heavy chain variable region sequence by at most 15 amino acids, preferably by at most 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids, more preferably by at most 1, 2, 3, 4 or 5 amino acids, and / or - From the group consisting of MF3178;MF3176;MF3163;MF3099;MF3307;MF6055;MF6056;MF6057;MF6058;MF6059;MF6060;MF6061;MF6062;MF6063;MF6064;MF6065;MF6066;MF6067;MF6068;MF6069;MF6070;MF6071;MF6072;MF6073 and MF6074 or at least a heavy chain variable region sequence, which differs by at most 15 amino acids, preferably by at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, more preferably by at most 1, 2, 3, 4, or 5 amino acids from the listed heavy chain variable region sequences.

[0150] The CDR sequences are changed, for example, for optimization purposes, preferably to improve the binding potency or stability of the antibody. Optimization is performed, for example, by mutagenesis procedures, after which the stability and / or binding affinity of the obtained antibody is preferably tested, and improved ErbB-2-specific or ErbB-3-specific CDR sequences are preferably selected. The skilled person is fully capable of generating antibody variants comprising at least one altered CDR sequence of the invention. For example, conservative amino acid substitutions are applied. Examples of conservative amino acid substitutions include the substitution of one hydrophobic residue, such as isoleucine, valine, leucine, or methionine, for another hydrophobic residue, and the substitution of one polar residue for another, such as, for example, arginine for lysine, glutamic acid for aspartic acid, or glutamine for asparagine.

[0151] A preferred antibody comprises a variable domain that binds ErbB-2, the VH chain of which has the amino acid sequence of VH chain MF2926; MF2930; MF1849; MF2973; MF3004; MF3958 (which is humanized MF2971); MF2971; MF3025; MF2916; MF3991 (which is humanized MF3004); MF3031; MF2889; MF2913; MF1847; MF3001, MF3003, or MF1898; or VH chain MF2926; MF2930; MF1849; MF2973 MF3004; MF3958 (which is humanized MF2971); MF2971; MF3025; MF2916; MF3991 (which is humanized MF3004); MF3031; MF2889; MF2913; MF1847; MF3001, MF3003 or MF1898, with up to 15, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, more preferably up to 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or combinations thereof with respect to the VH chain sequences mentioned above. The VH chain of the variable domain that binds ErbB-2 is preferably - MF1849; or - MF2971 or a humanized version thereof, which preferably comprises the amino acid sequence of MF3958; or - MF3004 or a humanized version thereof, the humanized version preferably comprising the amino acid sequence of MF3004 or a humanized version thereof, which comprises the amino acid sequence of MF3991. In one embodiment, the VH chain of the variable domain that binds ErbB-2 comprises the amino acid sequence of VH chain MF1849; or MF2971 or a humanized version thereof, the humanized version preferably comprising the amino acid sequence of MF3958; or MF3004 or a humanized version thereof, the humanized version preferably comprising the amino acid sequence of MF3991 or a humanized version thereof, which preferably has up to 15, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, more preferably up to 1, 2, 3, 4, or 5 amino acid insertions, deletions, substitutions, or a combination thereof, for each sequence. In a preferred embodiment, the VH chain of the variable domain that binds ErbB-2 comprises the amino acid sequence of MF3958; or, for the VH chain, comprises the amino acid sequence of MF3958 with up to 15, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, preferably 1, 2, 3, 4 or 5, amino acid insertions, deletions, substitutions, or a combination thereof.

[0152] The VH chain of the variable domain that binds Erb-B3 preferably comprises the amino acid sequence of VH chain MF3178;MF3176;MF3163;MF3099;MF3307;MF6055;MF6056;MF6057;MF6058;MF6059;MF6060;MF6061;MF6062;MF6063;MF6064;MF6065;MF6066;MF6067;MF6068;MF6069;MF6070;MF6071;MF6072;MF6073 or MF6074; or the VH chain MF3178;MF3176;MF3163;MF3099;MF3307 ;MF6055;MF6056;MF6057;MF6058;MF6059;MF6060;MF6061;MF6062;MF6063;MF6064;MF6065;MF6066;MF6067;MF6068;MF6069;MF6070;MF6071;MF6072;MF6073 or MF6074, and comprising an amino acid sequence having up to 15, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, more preferably 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or combinations thereof. The VH chain of the variable domain that binds Erb-B3 preferably comprises the amino acid sequence of MF3178, MF3176, MF3163, MF6058, MF6061 or MF6065; or with respect to the VH chain, the amino acid sequence of MF3178, MF3176, MF3163, MF6058, MF6061 or MF6065 with up to 15, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, more preferably up to 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or combinations thereof. In a preferred embodiment, the VH chain of the variable domain that binds ErbB-3 comprises the amino acid sequence of MF3178; or, for the VH chain, comprises the amino acid sequence of MF3178 with up to 15, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, more preferably 1, 2, 3, 4, or 5 amino acid insertions, deletions, substitutions, or a combination thereof. Preferably, said amino acid insertions, deletions and substitutions are not present in the CDR3 region.The above-mentioned amino acid insertions, deletions and substitutions are also preferably not present in the CDR1 and CDR2 regions.The above-mentioned amino acid insertions, deletions and substitutions are also preferably not present in the FR4 region.

[0153] Preferably, the antibody comprises at least the CDR1, CDR2, and CDR3 sequences of MF1849, MF2971, MF3958, MF3004, or MF3991, most preferably at least the CDR1, CDR2, and CDR3 sequences of MF3958. The antibody preferably comprises the CDR1, CDR2, and CDR3 sequences of MF3178, MF3176, MF3163, MF6058, MF6061, or MF6065, most preferably at least the CDR1, CDR2, and CDR3 sequences of MF3178.

[0154] Preferably, the ErbB-2 specific heavy chain variable region comprises the amino acid sequence of VH chain MF3958 with up to 15, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, more preferably up to 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or combinations thereof for said VH (preferably said insertions, deletions, substitutions are not in CDR1, CDR2 or CDR3). They are also preferably not in the FR4 region. The amino acid substitutions are preferably conservative amino acid substitutions.

[0155] Preferably, the ErbB-3 specific heavy chain variable region comprises the amino acid sequence of VH chain MF3178 with up to 15, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, more preferably up to 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or combinations thereof for said VH. The one or more amino acid insertions, deletions, substitutions or combinations thereof are preferably not in the CDR1, CDR2 and CDR3 regions of the VH chain. They are also preferably not in the FR4 region. The amino acid substitutions are preferably conservative amino acid substitutions.

[0156] Preferably, the ErbB-2 specific heavy chain variable region comprises the amino acid sequence of VH chain MF3991 with up to 15, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, more preferably up to 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or combinations thereof for said VH (preferably said insertions, deletions, substitutions are not in CDR1, CDR2 or CDR3). They are also preferably not in the FR4 region. The amino acid substitutions are preferably conservative amino acid substitutions.

[0157] Preferably, the ErbB-3 specific heavy chain variable region comprises the amino acid sequence of VH chain MF3178 with up to 15, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, more preferably up to 1, 2, 3, 4 or 5 amino acid insertions, deletions, substitutions or combinations thereof for said VH. The one or more amino acid insertions, deletions, substitutions or combinations thereof are preferably not in the CDR1, CDR2 and CDR3 regions of the VH chain. They are also preferably not in the FR4 region. The amino acid substitutions are preferably conservative amino acid substitutions.

[0158] Preferably, the first antigen-binding site of the antibody comprises at least the CDR1, CDR2, and CDR3 sequences of MF3958, or CDR1, CDR2, and CDR3 sequences that differ by at most three, preferably at most two, preferably at most one amino acid from the CDR1, CDR2, and CDR3 sequences of MF3958, and the second antigen-binding site comprises at least the CDR1, CDR2, and CDR3 sequences of MF3178, or CDR1, CDR2, and CDR3 sequences that differ by at most three, preferably at most two, preferably at most one amino acid from the CDR1, CDR2, and CDR3 sequences of MF3178.

[0159] Preferably, the bispecific antibody comprises i) a first antigen-binding site comprising an ErbB-2-specific heavy chain variable region and a light chain variable region comprising the CDR1, CDR2, and CDR3 sequences of MF3958, and ii) a second antigen-binding site comprising an ErbB-3-specific heavy chain variable region and a light chain variable region comprising the CDR1, CDR2, and CDR3 sequences of MF3178.

[0160] Preferably, the ErbB-2 specific heavy chain variable region has the MF3958 sequence and the ErbB-3 specific heavy chain variable region has the MF3178 sequence. This combination is also referred to as the PB4188 antibody. Preferably, the PB4188 antibody is afucosylated.

[0161] Preferably, the bispecific antibody comprises a "heavy chain for ErbB-2 binding" as shown in the sequence listing, part 4, and a "heavy chain for ErbB-3 binding" as shown in the sequence listing, part 4.

[0162] Preferably, the antigen-binding site of the bispecific antibody is a common light chain as defined herein, preferably a germline common light chain, preferably a rearranged germline human kappa light chain IgVκ1-39. * 01 / IGJκ1 * 01 or a fragment or functional derivative thereof (nomenclature according to the IMGT database World Wide Web at imgt.org). Rearranged germline human kappa light chain IgVκ1-39 * 01 / IGJκ1 *The terms IGKV1-39 / IGKJ1, huVκ1-39 light chain, or the shortened form huVκ1-39, are used. The light chain may have 1, 2, 3, 4, or 5 amino acid insertions, deletions, substitutions, or combinations thereof. The 1, 2, 3, 4, or 5 amino acid substitutions mentioned are preferably conservative amino acid substitutions, and the insertions, deletions, substitutions, or combinations thereof are preferably not in the CDR3 region of the VL chain, and preferably not in the CDR1, CDR2, or CDR3 region or the FR4 region of the VL chain. Preferably, the first antigen-binding site and the second antigen-binding site comprise the same light chain variable region, or rather a common light chain. Preferably, the light chain variable region comprises a CDR1 with the sequence (RASQSISSYLN), a CDR2 with the sequence (AASSLQS), and a CDR3 with the sequence (QQSYSTPPT). Preferably, the light chain variable region comprises the consensus light chain sequence shown in FIG.

[0163] Various methods are available for producing bispecific antibodies and are discussed in WO 2015 / 130173. One method involves expressing two different heavy chains and two different light chains in a cell and harvesting the antibodies produced by the cell. The antibodies produced in this way typically contain a collection of antibodies with different combinations of heavy and light chains, some of which are the desired bispecific antibodies. The bispecific antibodies can then be purified from the collection.

[0164] The ratio of bispecific antibodies to other antibodies produced by the cells can be increased in various ways. Preferably, this ratio is increased by not expressing two different light chains in the cells, but by expressing two essentially identical light chains. This concept is in the art also referred to as the "common light chain" method. If an essentially identical light chain works together with two different heavy chains to allow the formation of variable domains with different antigen binding sites and associated different binding properties, the ratio of bispecific antibodies to other antibodies produced by the cells is significantly improved over the expression of two different light chains. The ratio of bispecific antibodies produced by the cells can be further improved by stimulating the pairing of two different heavy chains with each other versus the pairing of two identical heavy chains. In this technology, various methods are described by which such heterodimerization of heavy chains can be achieved. A preferred method is described in PCT Application No. PCT / NL2013 / 050294 (WO 2013 / 157954A1), which is incorporated herein by reference. Methods and means for producing bispecific antibodies from a single cell are disclosed, thereby providing a means to favor the formation of bispecific antibodies over the formation of monospecific antibodies.

[0165] Although features are described herein as part of the same or separate embodiments for clarity and conciseness of description, it will be understood that the scope of the invention may include embodiments having all or a partial combination of the described features. [Brief description of the drawings]

[0166] [Figure 1] a) the common light chain amino acid sequence. b) the common light chain variable region DNA sequence and translation (IGKV1-39 / jk1). c) the common light chain constant region DNA sequence and translation. d) the IGKV1-39 / jk5 common light chain variable region translation. e) the V-region IGKV1-39A. f) the common light chain CDR1, CDR2 and CDR3. [Figure 2-1]IgG heavy chain for the generation of bispecific molecules. a) CH1 region. b) hinge region. c) CH2 region. d) CH3 domain containing the variations L351K and T366K (KK). e) CH3 domain containing the variations L351D and L368E (DE). [Figure 2-2] IgG heavy chain for the generation of bispecific molecules. e) CH3 domain containing the variations L351D and L368E(DE). [Diagram 3] Amino acid alignment of mutants of MF3178. Dots indicate the same amino acid as in MF3178 at that position. The CDR1, CDR2, and CDR3 sequences of MF3178 are in bold and underlined. The CDRs of the mutants are in the corresponding positions. [Figure 4-1] Sequence information for some of the nucleic acid and peptide molecules referred to in this application: Sequence 4A (ErbB-2 specific). [Figure 4-2] Sequence information for some of the nucleic acid and peptide molecules referred to in this application: Sequence 4A (ErbB-2 specific). [Figure 4-3] Sequence information for some of the nucleic acid and peptide molecules referred to in this application: Sequence 4A (ErbB-2 specific). [Figure 4-4] Sequence information for some of the nucleic acid and peptide molecules referred to in this application: Sequence 4A (ErbB-2 specific). [Figure 4-5] Sequence information for some of the nucleic acid and peptide molecules referred to in this application: Sequence 4A (ErbB-2 specific). [Figure 4-6] Sequence information for some of the nucleic acid and peptide molecules referred to in this application: Sequence 4A (ErbB-2 specific); Sequence 4B (ErbB-3 specific). [Figure 4-7] Sequence information for some of the nucleic acid and peptide molecules mentioned in this application: Sequence 4B (ErbB-3 specific). [Figure 4-8] Sequence information for some of the nucleic acid and peptide molecules mentioned in this application: Sequence 4B (ErbB-3 specific). [Figure 4-9]Sequence information for some of the nucleic acid and peptide molecules referred to in this application.Sequence 4C: The heavy chain for the ErbB-2 binding arm and the heavy chain for the ErbB-3 binding arm in the bispecific antibody described herein. [Figure 4-10] Sequence information for some of the nucleic acid and peptide molecules referred to in this application. Sequence 4D HER2-specific VH sequence and HER3-specific VH sequence. [Figure 4-11] Sequence information for some of the nucleic acid and peptide molecules referred to in this application. Sequence 4D HER2-specific VH sequence and HER3-specific VH sequence. [Figure 4-12] Sequence information for some of the nucleic acid and peptide molecules referred to in this application. Sequence 4D HER2-specific VH sequence and HER3-specific VH sequence. [Figure 4-13] Sequence information for some of the nucleic acid and peptide molecules referred to in this application. Sequence 4D HER2-specific VH sequence and HER3-specific VH sequence. [Figure 4-14] Sequence information for some of the nucleic acid and peptide molecules referred to in this application. Sequence 4D HER2-specific VH sequence and HER3-specific VH sequence. [Diagram 5] 1 is a diagram of the mechanism of action and therapeutic method of an exemplary HER2 / 3 bispecific antibody administered in the present invention. After selective docking of the bispecific antibody to HER2, binding of NRG1 to HER3 is prevented by selectively binding the second arm, which in turn prevents phosphoinositide 3-kinase / protein kinase B (PI3K / AKT)-mediated cell proliferation / survival. EXAMPLES

[0167] As used herein, "MFXXXX" (where X is independently a number from 0 to 9) refers to a Fab comprising a variable domain, where the VH has the amino acid sequence identified by the four digits depicted in Figure 3 or 4. Unless otherwise noted, the light chain variable region of the variable domain typically has the sequence of Figure 1a. The light chain in the examples has the sequence depicted in Figure 1b. "MFXXXX VH" refers to the amino acid sequence of the VH identified by the four digits. The MF further comprises a constant region of the light chain and a constant region of the heavy chain that typically interacts with the constant region of the light chain. The VH / variable regions of the heavy chain are distinct, typically CH3 regions, where one of the heavy chains has a KK mutation in its CH3 domain and the other has a complementary DE mutation in its CH3 domain of Figures 2d and 2e (see reference PCT / NL2013 / 050294 (published as WO 2013 / 157954)). In the examples, the bispecific antibody has a KK / DE CH3 heterodimerization domain, an Fc tail with a CH2 domain and a CH1 domain as shown in FIG. 2, a common light chain as shown in FIG. 1a, and a VH designated by the MF number.

[0168] Example 1: A Phase I / II Study of the Bispecific Antibody MF3958 x MF3178, a Full-Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors Exam duration: Twenty-eight patients were recruited for the dose escalation portion of the study (Part 1). Part 2 of the study will be the dose expansion phase. The total duration of Part 2 will be approximately 25-32 months, however, the actual duration will be affected by several variables, e.g., overall subject recruitment rate.

[0169] Number of patients: Twenty-eight (28) patients were enrolled in Part 1. For Part 2, at least 20 evaluable patients, and up to approximately 40 patients, may be enrolled in the arm with invasive mucinous adenocarcinoma or advanced / metastatic non-small cell lung cancer (NSCLC) with documented NRG1 fusion.

[0170] Patients who did not complete at least two cycles of study treatment for reasons other than disease progression were not evaluable for efficacy and were replaced in their respective arms.

[0171] This example describes the second part of this study.

[0172] Purpose of the test:

[0173] [Table 1]

[0174] [Table 2]

[0175] Study design: This is a Phase I / II, open-label, multicenter, multinational, dose-escalation, single-arm assignment study to evaluate the safety, tolerability, PK, PD, immunogenicity, and antitumor activity of MF3958 × MF3178.

[0176] The study is designed in two parts: Part 1 Part 1 of the study included the study of nine dose levels: 40 mg, 80 mg, 160 mg in one patient cohort and 240 mg, 360 mg, 480 mg, 600 mg, 750 mg, and 900 mg in three patient cohorts. MF3958 x MF3178 was initially given over approximately 60 minutes on day 1 of a 3-week treatment cycle. During Part 1, the infusion duration was extended to 2 hours with the option to increase to a maximum of 4 hours to mitigate infusion-related reactions (IRR). There were no dose-limiting toxicities (DLTs) at any of the dose levels. Three additional patients were dosed in each of the 600 mg and 750 mg cohorts to have sufficient PK information. Because the MTD was not achieved at the 900 mg dose level, the Data Review Committee (DRC) for MF3958 x MF3178-CL01 decided to assign the 750 mg dose level as the RP2D for this study based on cumulative safety, available PK data, and PK simulations.

[0177] Part 2 Part 2 will include further characterization of the safety and tolerability of selected dose levels of MF3958 x MF3178, as well as an assessment of CBR, defined as the proportion of patients with CR, PR, or durable SD (SD of at least 12 weeks duration) in an expansion group of selected patient populations.

[0178] A weekly dosing regimen using 4-week cycles will be evaluated in newly recruited patients consisting of a fixed dose of 400 mg weekly for the first two cycles, with a dose of 800 mg for the first dose. Beginning with cycle 3, MF3958 x MF3178 will be given at a dose of 400 mg weekly for 3 weeks, followed by 1 week off. Mandatory pre-medications will be administered to mitigate IRR. However, corticosteroids will only be mandatory prior to the cycle 1 day 1 dose and will only be used for subsequent infusions at the investigator's discretion to manage IRR.

[0179] The safety of the weekly schedule will be reviewed during the run-in period after the first five patients treated have completed at least two treatment cycles. The DRC will review all safety data with a focus on the incidence of grade 3-4 toxicity, the incidence and severity of IRRs, and compliance. If the DRC review concludes that toxicity is unacceptable, the sponsor will continue enrolling patients on the 3-week cycle dosing regimen until a sufficient number of patients per cohort have been enrolled.

[0180] Intrapatient dose escalation will not be permitted in Part 2.

[0181] Patient populations of interest evaluated in the second part of the study are: NSCLC with NRG1 fusion document

[0182] At least 20 and up to approximately 40 patients may be enrolled in each arm (C-F) with a minimum of 10 patients per cohort treated at the recommended weekly dose. Previously closed cohorts may be reopened.

[0183] Treatment duration Patients in both Parts 1 and 2 of this study may continue to be treated until disease progression, death, unacceptable toxicity, or discontinuation for any other reason.

[0184] Data Review Committee (DRC): All dose escalation decisions in Part 1 were made by a DRC that was mandated to review all available safety and PK data. DRC participants included the principal investigators (or their designees), the sponsor's medical director, the study medical monitor, the study pharmacovigilance physician, the study project manager, the study statistician, and designated experts as needed (e.g., clinical pharmacology experts).

[0185] In Part 2, the DRC will review the data following completion of the safety trial period for the once-weekly dose before expanding the once-weekly dosing regimen in all subsequent patients.

[0186] Test evaluation: The study will consist of a molecular prescreening assessment until a 4-week (28-day) screening period, followed by successive treatment cycles until treatment is withdrawn or terminated for any use. Treatment cycle duration will be 3 weeks (21 days) for patients treated at the initial recommended dose in Part 2 and 4 weeks (28 days) for patients treated at the weekly recommended dose in Part 2. All patients will attend an end-of-treatment visit within 1 week of completing treatment, with the final study visit being 30 days after treatment completion or study discontinuation.

[0187] Patients who do not proceed to consent to completing the final study visit or who withdraw consent will be followed up every 3 months for up to 2 years (approximately) to ascertain disease progression and / or survival status until the initiation of their next anti-cancer treatment.

[0188] If ongoing evaluation of safety data and available PK, PD, and antitumor activity data during the study suggests that alternate dosing frequencies should be evaluated or other patient populations should be evaluated in Part 2, these modifications will be identified in a protocol amendment prior to initiating these evaluations.

[0189] Molecular pre-screening and screening: Molecular pre-screening will be performed in a local laboratory certified to perform molecular screening for NRG1 fusions. To initiate pre-screening, patients must meet one of the following criteria: Histological diagnosis of IMA and documented no EGFR / ALK alterations. Note: Patients with IMA who do not have a pre-screening test for NRG1 fusions can be enrolled in this study. or Pathological examination does not permit the diagnosis of IMA, but the investigator suspects IMA based on symptoms, imaging features (e.g., focal consolidation, multiple bilateral nodules or consolidation), non-smoker status, and documented absence of EGFR / ALK alterations.

[0190] A molecular pre-screening informed consent form (ICF) must be signed by NSCLC patients identified for potential study participation, after which fresh or archival tumor tissue is donated for analysis for determination of NRG1 fusion status. Testing can be performed at any time in the natural history of the disease (e.g., at diagnosis, during first line of treatment, at progression, etc.) up to one year prior to day 1 of cycle 1. Fresh tumor samples (formalin-fixed paraffin-embedded (FFPE)) or archival tumor samples less than one year old are required for evaluation of the presence of NRG1 fusion. Samples shall be donated to a local laboratory qualified for testing by molecular profiling (PCR, next generation sequencing (DNA or RNA) or FISH) of NRG1 fusion status. Patients with a positive local NRG1 fusion result are then eligible to sign the study's ICF and can enter the study if they wish.

[0191] Explanation of this study and consent form The ICF for this study must be signed by all patients before any screening procedures or assessments are performed. Screening assessments must be performed within 4 weeks prior to Cycle 1 Day 1, with the exception of serum pregnancy test, which must be performed within 7 days of Cycle 1 Day 1. To be considered for screening, a baseline required tumor sample is required, preferably a block from fresh tissue or archival tissue. The sponsor will indicate a preference for fresh tissue. Archival is acceptable and must have been taken within 2 years of screening, except for NSCLC, which must be within 1 year. It should be noted that for NSCLC patients, a baseline biopsy for screening is still required even if a pre-screening biopsy sample is provided for the NRG1 pre-screening on-site study. After completion of all required screening assessments and confirmation of all eligibility criteria, the patient may begin dosing on Cycle 1 Day 1.

[0192] Safety assessment Intercurrent illnesses will be captured at baseline, and AEs and concomitant therapies will be monitored throughout study participation. Safety assessments will include Eastern Cooperative Oncology Group (ECOG) fitness status, physical examination (including height and weight), vital signs, and review of electrocardiogram (ECG). Cardiac function testing of left ventricular ejection fraction (LVEF) will also be performed at screening, end of cycle 4 (or day 1 of cycle 5), end of study visit, and at any time during the study if clinically indicated. Laboratory evaluations will include clinical chemistry, hematology, coagulation, urinalysis, and pregnancy testing. Note that cytokine panel analysis was performed through August 1, 2017.

[0193] On all MF3958 x MF3178 dosing days, patients must remain in the clinic for at least 60 minutes from the end of infusion (or longer if PK samples are required) for observation and repeat vital signs before being discharged from the clinic. Further safety evaluations will be performed as clinically indicated and, if necessary, will extend the length of stay at the clinic based on the investigator's discretion.

[0194] Immunogenicity assessment Serum titers of anti-MF3958xMF3178 antibodies will be measured on day 1 prior to dosing for each of cycles 1, 2, 3, 4, and then every fourth cycle thereafter (cycles 8, 12, 16, etc.), as well as at the end of study visit and final study visit, allowing for a window of approximately 3 days prior to administration of MF3958xMF3178.

[0195] Pharmacokinetic evaluation Initial recommended dosing schedule for Parts 1 and 2: In Cycle 1, blood samples will be collected for PK analysis pre-dose, at the end of infusion (EOI), 1, 2, 4, 8, 24 hours after EOI, then on Day 4 (or Day 3), Day 8, and Day 15. In Cycles 2-4, only pre-dose and EOI blood samples will be collected.

[0196] Part 2 recommended weekly dosing schedule: In cycle 1, blood samples are collected for PK analysis pre-dose, 2, 4, 24 hours after EOI, then pre-dose on days 8 and 15, and pre-dose and EOI on day 22. In cycles 2 and 3, pre-dose and EOI blood samples are collected on day 15. In cycle 4, blood samples are collected pre-dose on day 1, and pre-dose and EOI on day 15. Thereafter, every two cycles (cycles 6, 8, 10, etc.), a pre-dose blood sample is collected on day 15.

[0197] Tumor assessment Tumor assessments will be per investigator assessed per RECIST version 1.1. Imaging will be obtained at screening and at the end of every 2 cycles of treatment for patients receiving a 3-weekly cycling regimen, and every 6 weeks for patients receiving a 4-weekly cycling regimen.

[0198] Biomarker and Pharmacokinetic Assessment A series of biomarker and pharmacodynamic studies will be performed on archived and / or fresh tumor sample material and / or blood (liquid biopsy), depending on the availability of archived or existing tumor tissue, consent for further tumor samples, and consent for specific biomarker studies.

[0199] The following candidate biomarkers will be evaluated if sufficient samples are available: • HER2, HER3, HER2:HER3 dimerization, phosphorylated HER2 (pHER2) and HER3 (pHER3) and heregulin; Use circulating plasma tumor DNA (ctDNA) and tumor sample DNA (subject to availability) to test for mutations in cancer genes, including those involved in HER2 and HER3 signaling. • Phosphorylated molecules in the MAPK and AKT signaling pathways; • Fc gamma receptor polymorphisms; • Circulating tumor cells for HER2; Heregulin-gene fusion

[0200] Germline DNA evaluation is not included (except for Fc gamma receptor polymorphisms).

[0201] At baseline, patients are requested to provide the requisite tumor sample tissue, preferably a block that may be from fresh or archived tissue. The sponsor indicates a preference for fresh tissue. Archives are acceptable and must be taken within 2 years of screening, but for NSCLC, must be within 1 year. In addition, patients are requested to optionally provide tumor samples / biopsies at the end of cycle 4 and optionally at the end of treatment visits.

[0202] Blood samples are also taken at these time points for the purposes of liquid biopsy testing.

[0203] Eligibility Criteria: The study will enroll patients with NSCLC.

[0204] General inclusion criteria for Part 2 1. 18 years of age or older; 2. At least one measurable lesion by RECIST 1.1, 3. Physical status of ECOG 0 or 1; 4. A life expectancy of at least 12 weeks; 5. Toxicity resulting from prior anticancer therapy classified as Grade 1 (as defined by NCI CTCAE ver. 4.03), excluding alopecia and lymphopenia, assessed as non-clinically significant Grade 2 neurosensory toxicity; 6. At least 4 weeks between the last radiation therapy received and the first scheduled day of MF3958 × MF3178 dosing (excluding up to 1 × 8 Gy for pain relief), 7. Complete recovery from major surgery (stable and acceptable grade 2 or less toxicity), 8. Screening test values: Absolute neutrophil count ≥ 1.5 × 10 9 / L, without colony-stimulating factor support; b. Platelets ≧100×10 9 / L, c. Hemoglobin ≥ 9g / dL or ≥ 2.2mmol / L (not transfusion dependent), d. Total bilirubin <1.5 times the upper limit of normal (ULN) (unless due to Gilbert syndrome), e. AST (SGOT) ≤ 2.5 x ULN, ALT (SGPT) ≤ 2.5 x ULN, ≤ 5 x ULN for patients with advanced solid tumors with liver metastases, patients with confirmed bone metastases are allowed for the study in which an elevation in ALP > 5 x ULN was isolated; f. Serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate (GFR) > 50 mL / min based on the Cockroft-Gault equation; g. Coagulation function (INR and aPTT ≤ 1.5 ULN unless limited by therapeutic anticoagulants) h. Urinary protein ≦2+ (measured by dipstick) or ≦100 mg / 24-hour urine; 9. At baseline, be able to provide a mandatory tumor biopsy sample (FFPE), preferably a block from fresh (preferred) or archived tissue. Archived tissue must be collected within 2 years prior to screening, except for NSCLC, which must be within 1 year. 10. Available negative pregnancy test as defined by urine or blood human chorionic gonadotropin (hCG) test at screening and within 7 days of cycle 1, day 1 in fertile women (defined as women ≤50 years of age or with a history of amenorrhea for ≤12 months prior to study enrollment), 11. Fertile sexually active male and female patients must agree to use effective birth control methods (e.g., spermicides, oral or non-oral contraceptives, and / or barrier methods using intrauterine devices) throughout the duration of the study and for 6 months after the last dose of MF3958 x MF3178. Note that infertility in female patients must be confirmed in the patient's medical records and must be defined as one of the following: surgical hysterectomy with bilateral oophorectomy, bilateral tubal ligation, natural menopause with last menstrual period >1 year ago; radiation-induced oophorectomy with last menstrual period >1 year ago; chemotherapy-induced menopause with a 1-year interval since last menstrual period, 12. Be able to provide informed, written consent prior to any study-specific screening procedures, with the understanding that consent may be withdrawn by the patient at any time without prior diagnosis; 13. Able to understand mandatory and optional protocol requirements, willing and able to comply with study protocol procedures, and have signed the main informed consent document. Additional consent is required for any biopsy sampling (tissue and / or blood) and long-term sample storage. 14. Patients with metastatic cancer whose disease has progressed after treatment with all available therapies known to provide clinical benefit. 15. Unresectable or metastatic NSCLC meeting one of the following criteria: Biochemically proven invasive mucinous adenocarcinoma (IMA). Note: IMA patients who have not had a pre-screening test for NRG1 fusions are eligible to enter this study. or • NSCLC with documented NRG1 fusion determined in a qualified local laboratory by molecular profiling using methods such as PCR, next generation sequencing (DNA or RNA) or FISH in patients without known driver mutations or fusions in the EGFR / ALK genes. 16. Documented disease progression per investigator assessment on at least one line of standard therapy in the locally advanced or metastatic setting.

[0205] Statistical analysis: Part 1 and Part 2 Antitumor and clinical benefit variables are summarized descriptively for each group in Part 2. Where appropriate, variables are presented in terms of absolute and relative change from baseline. Categorical data are presented as percentages and frequency tables.

[0206] Where appropriate, data from patients who received what is identified as the MTD or MRD in Part 1 and from patients who received the same dose in Part 2 may be combined, summarized, and summarized separately.

[0207] The frequency and nature of serious and non-serious AEs will be assessed using absolute and relative frequencies and coded using the MedDRA Encyclopedia.

[0208] Part 1 Data evaluation is descriptive in nature. Patient demographics, disease characteristics, and pharmacokinetic and pharmacodynamic variables will be summarized at each dose level. The frequency and nature of DLTs will also be summarized at each dose level.

[0209] Part 2 With N=20 per cohort in Part 2, a clinically meaningful observed correlation coefficient of at least 0.38 would be distinguishable from zero with 95% confidence, and lower, non-clinically meaningful observed correlations would not be distinguishable from zero. Hence, 20 subjects per cohort in Part 2 is considered sufficient to explore the association between the antitumor activity of MF3958×MF3178 and disease-related biomarkers. If signs of clinical activity are seen, additional patients may be recruited, up to a total of approximately 40. With 40 patients, for example, a true clinical response rate of 10% to 50% can be estimated with reasonable precision of approximately ±5% to ±8%.

[0210] PK parameters are summarized for each cohort in Part 1 and for each tumor group in Part 2. Arithmetic and geometric means are provided in addition to median, range, SD, and CV%. AUC is calculated by the trapezoidal rule. Serum concentration profiles versus time are plotted for each group.

[0211] Example 2 Treatment of patients whose cancer has progressed after prior afatinib therapy with a HER2-HER3 bispecific antibody

[0212] A 38-year-old woman diagnosed with NSCLC with histological invasive mucinous adenocarcinoma was treated with MF3958×MF3178. This study shows that MF3958×MF3178 stabilizes the tumor in terms of size or lesions. This treatment prevents further tumor growth.

[0213] Molecular profiling of tumors: Analysis of tumor tissue obtained from the lung demonstrated an SDC4-NRG1 fusion, and the tumor genome showed no mutations in EGFR, KRAS, EGFR, cKIT-BRCA1-2, MET, ROS, RET, or ALK. The analysis was performed using Oncomine, a targeted DNA sequencing method designed for cancer research and that allows the analysis of multiple biomarkers, including fusions, insertions / deletions (indels), single nucleotide variants, and copy number variations. The results were confirmed by RNA-seq and anchored multiplex PCR (Archer).

[0214] Previous treatment: The patient received adjuvant treatment with cisplatin, carboplatin, and pemetrexed for 4 months. Within 5 to 6 months, the patient presented with bilateral pulmonary recurrence. The patient was then treated with afatinib for approximately 11 months until new progression of the cancer was detected. The patient entered this study within 2 months of stopping afatinib treatment.

[0215] Clinical status at study entry: At the time of enrollment in this study, the patient presented with NSCLC with metastatic tumor extension in the lungs and pleura. The patient was presented with a good general level of condition (ECOG Physical Status of 1). The ECOG Physical Status scale describes the patient's level of functioning in terms of their ability to care for themselves, their daily activities, and their physical abilities. An ECOG score of 1 reflects that the patient has limited physically strenuous activity but is ambulatory and able to perform tasks or work of a light or sedentary nature.

[0216] Treatment with bispecific antibody MF3958 x MF3178: Treatment consisted of the bispecific antibody MF3958 x MF3178 administered in a weekly regimen. The first dose was administered with pre-medication. A total of eight cycles were administered over the eight-month study period.

[0217] The weekly dosing regimen with 4-week cycles will consist of a fixed dose of 400 mg once weekly for the first two cycles, followed by a dose of 800 mg for the first dose. Beginning with cycle 3, MF3958 x MF3178 will be given at a dose of 400 mg weekly for 3 weeks, followed by a 1-week break. Mandatory pre-medications will be administered to mitigate IRR. However, corticosteroids will only be mandatory prior to the cycle 1 day 1 dose, and will only be used for subsequent infusions at the investigator's discretion to manage IRR.

[0218] Safety: No patient experienced any severe episodes of study drug-related toxicity.

[0219] Efficacy: Disease was assessed with measurable disease in the lungs by using CT scans. Antitumor activity and clinical benefit assessed by RECIST version 1.1, which determined objective overall response rate (ORR), duration of response (DOR), progression-free survival (PFS), and survival. Four tumor assessments reported stable disease (RECIST version 1.1). This study shows that MF3958 x MF3178 stabilizes tumors in terms of size or lesions. This treatment prevents further tumor growth.

[0220] Example 3 Treatment after chemotherapy and afatinib with a HER2-HER3 bispecific antibody in patients with NRG1 fusions.

[0221] Alternatively to the dosing regimen of Example 2, the pharmaceutical agent may be provided on a biweekly dosing schedule as follows: The biweekly schedule will consist of 750 mg of MF3958 x MF3178 over 4 hours for the first infusion, then over 2 hours for each subsequent infusion every other week for a 4 week cycle. Pre-medications will also be included to manage IRR (infusion related reactions) consisting of antipyretics and antihistamines for all infusions. Corticosteroids will be included prior to the cycle 1 dose on Day 1, and will be administered thereafter at the investigator's discretion to manage IRR.

[0222] Example 4 Treatment after chemotherapy and afatinib with a HER2-HER3 bispecific antibody in patients with NRG1 fusions.

[0223] Alternatively to the dosing regimen of Example 3, the pharmaceutical agent may be provided on an every three week dosing schedule as follows: The every 3 weeks schedule will consist of 750 mg MF3958 x MF3178 over 4 hours for the first infusion, then over 2 hours for each subsequent infusion every other week for a 4 week cycle. Pre-medications will also be included to manage IRR (infusion related reactions) consisting of antipyretics and antihistamines for all infusions. Corticosteroids will be included prior to the cycle 1 dose on day 1, and will be administered thereafter at the investigator's discretion to manage IRR.

Claims

1. 1. A pharmaceutical composition comprising a bispecific antibody comprising a variable domain comprising a first antigen binding site that binds an extracellular portion of ErbB-2 and a variable domain comprising a second antigen binding site that binds an extracellular portion of ErbB-3, said composition being for use in treating a subject with an ErbB-2 and ErbB-3 positive cancer, wherein cells of the cancer comprise a neuregulin-1 (NRG1) fusion gene comprising at least a portion of the NRG1 gene fused to sequences from different chromosomal locations, and wherein the cancer in the subject has been previously treated with a monospecific bivalent antibody comprising an antigen binding site that binds the extracellular portion of ErbB-2 or the extracellular portion of ErbB-3, or previously treated with a tyrosine kinase inhibitor (TKI) of ErbB-2 or chemotherapy.

1. A pharmaceutical composition comprising an antibody that is progressing after receiving a prior therapy, or a combination thereof, wherein the antibody comprises an ErbB2-specific heavy chain variable region having CDR1, CDR2 and CDR3 having the sequences AYYIN, RIYPGSGYTSYAQKFQG and PPVYYDSAWFAY, respectively, and the antibody comprises an ErbB3-specific heavy chain variable region having CDR1, CDR2 and CDR3 having the sequences GYYMH, WINPNSGGTNYAQKFQG and DHGSRHFWSYWGFDY, respectively, and a light chain variable region comprising CDR1 having the sequence QSISSY, CDR2 having the sequence AAS, and CDR3 having the sequence QQSYSTPPT, and administration of the antibody is according to a weekly, biweekly or every three weeks dosing regimen of 750 mg.

2. The pharmaceutical composition for use according to claim 1, wherein the antibody is administered as a biweekly dose of 750 mg.

3. The pharmaceutical composition for use according to claim 1, wherein the antibody is administered as a dose of 750 mg every three weeks.

4. The pharmaceutical composition for use according to any one of claims 1 to 3, wherein the subject is a human subject.

5. 5. The pharmaceutical composition for use according to any one of claims 1 to 4, wherein the TKI is one or more of lapatinib, canertinib, neratinib, tucatinib, CP-724714, taloloxitinib, mubritinib, afatinib, valitinib, and dacomitinib.

6. The pharmaceutical composition for use according to any one of claims 1 to 5, wherein the TKI is afatinib.

7. 2. The pharmaceutical composition for use according to claim 1, wherein said monospecific bivalent antibody comprising an antigen binding site that binds the extracellular portion of ErbB-3 comprises patritumab, seribantumab, lumuletuzumab, elgemtumab, GSK2849330, KTN3379 or AV-203.

8. The pharmaceutical composition for use according to any one of claims 1 to 7, wherein said NRG1 fusion gene comprises at least the 3' end of said NRG1 gene fused to a 5' sequence from a different chromosomal location.

9. The pharmaceutical composition for use according to any one of claims 1 to 8, wherein said cancer cells are driven by said NRG1 fusion gene.

10. The pharmaceutical composition for use according to any one of claims 1 to 9, wherein the cancer is a recurrent or metastatic cancer.

11. The pharmaceutical composition for use according to any one of claims 1 to 10, wherein the cancer is breast cancer, ovarian cancer, lung cancer, non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma, renal cell adenocarcinoma, sarcoma, gallbladder cancer, bladder cancer, bile duct cancer, head and neck cancer, prostate cancer, uterine cancer, sinonasal teratoma carcinosarcoma, colorectal adenocarcinoma, liver cancer or colorectal cancer.

12. The pharmaceutical composition for use according to any one of claims 1 to 11, wherein the cancer is non-small cell lung cancer.

13. The pharmaceutical composition for use according to any one of claims 1 to 12, wherein the cancer is invasive mucinous adenocarcinoma.

14. The pharmaceutical composition for use according to any one of claims 1 to 13, wherein the cancer is pancreatic ductal adenocarcinoma.

15. The pharmaceutical composition for use according to any of claims 1 to 14, wherein said NRG1 fusion gene expresses a protein comprising an NRG1 EGF-like domain.

16. The pharmaceutical composition for use according to any one of claims 1 to 15, wherein said NRG1 fusion gene is a fusion of NRG1 with a gene on human chromosome 8.

17. The NRG1 fusion gene is a fusion gene that ...

17. The pharmaceutical composition for use according to any one of claims 1 to 16, wherein the fusion is with the 5' sequence of one of the genes selected from the group consisting of: 2IL1, RAB3IL1, RBPMS, ROCK1, SDC4, SETD4, SLC3A2, SLC4A4, SMAD4, STAU3, THAP7, THBS1, TNC, TNFRSF10B, TNKS, TSHZ2, VAMP2, VTCN1, WHSC1L1, WRN and ZMYM2.

18. The pharmaceutical composition for use according to claim 17, wherein said NRG1 fusion gene is a fusion of the 3' end of said NRG1 gene with the 5' sequence of said gene SDC4.

19. The antibody, i) ErbB2-specific heavy chain variable region sequence: QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS; and a light chain variable region comprising a CDR1 having the sequence QSISSY, a CDR2 having the sequence AAS, and a CDR3 having the sequence QQSYSTPPT; and / or ii) ErbB3-specific heavy chain variable region sequence: QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS; and a light chain variable region comprising a CDR1 having the sequence QSISSY, a CDR2 having the sequence AAS, and a CDR3 having the sequence QQSYSTPPT A pharmaceutical composition for use according to any one of claims 1 to 18, comprising:

20. A pharmaceutical composition for use according to any one of claims 1 to 19, wherein the antibody comprises the light chain variable region sequence: DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSSTPPTFGQGTKVEIK.

21. A pharmaceutical composition for use according to any one of claims 1 to 20, wherein the antibody is an IgG.

22. The pharmaceutical composition for use according to any one of claims 1 to 21, wherein the antibody is human IgG1.

23. The pharmaceutical composition for use according to any one of claims 1 to 22, wherein the antibody has ADCC activity.

24. A pharmaceutical composition for use according to any one of claims 1 to 23, wherein the antibody is afucosylated.

25. 25. The pharmaceutical composition for use according to any one of claims 1 to 24, wherein said chemotherapy comprises gemcitabine, capecitabine, carboplatin, taxanes, docetaxel or paclitaxel, 5-fluorouracil (with or without radiotherapy), vinorelbine, mitoxantrone, vinblastine, cisplatin (or pemetrexed), oxaliplatin, carboplatin, ifosfamide, mitomycin C, vindesine, etoposide, Folfox (i.e. a combination of 5-fluorouracil, leucovorin, and oxaliplatin) or Folfiri (i.e. a combination of leucovorin, 5-fluorouracil and irinotecan), Folfirinox (a combination of leucovorin, 5-fluorouracil, irinotecan and oxaliplatin) or any combination thereof.

26. A pharmaceutical composition comprising a bispecific antibody comprising a variable domain comprising a first antigen-binding site which binds an extracellular portion of ErbB-2 and a variable domain comprising a second antigen-binding site which binds an extracellular portion of ErbB-3, said composition being for use in the manufacture of a medicament for the treatment of a subject having an ErbB-2 and ErbB-3 positive cancer, wherein cells of the cancer comprise a neuregulin-1 (NRG1) fusion gene comprising at least a portion of the NRG1 gene fused to sequences from different chromosomal locations, and wherein the cancer in the subject has been previously treated with a monospecific bivalent antibody comprising an antigen-binding site which binds the extracellular portion of ErbB-2 or the extracellular portion of ErbB-3, or with a tyrosine kinase inhibitor (TKI) of ErbB-2 or chemotherapy.

4. The pharmaceutical composition of claim 1, wherein the antibody comprises an ErbB2 specific heavy chain variable region having CDR1, CDR2 and CDR3 having the sequences AYYIN, RIYPGSGYTSYAQKFQG and PPVYYDSAWFAY, respectively, and the antibody comprises an ErbB3 specific heavy chain variable region having CDR1, CDR2 and CDR3 having the sequences GYYMH, WINPNSGGTNYAQKFQG and DHGSRHFWSYWGFDY, respectively, and a light chain variable region comprising CDR1 having the sequence QSISSY, CDR2 having the sequence AAS, and CDR3 having the sequence QQSYSTPPT, and administration of the antibody is according to a weekly, biweekly or every three weeks dosing regimen of 750 mg.